molecule_chembl_id,target_chembl_id,target_pref_name,standard_type,standard_relation,standard_value,standard_units,assay_chembl_id,assay_type,assay_description,document_chembl_id,readout,smiles
CHEMBL128,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,9.3,nM,CHEMBL618143,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,CHEMBL1130196,IC50,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
CHEMBL364005,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,34.0,nM,CHEMBL880643,B,Inhibitory activity against 5-hydroxytryptamine 3 receptor expressed in NG 108 cells,CHEMBL1141036,IC50,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1
CHEMBL376324,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,275.0,nM,CHEMBL853933,B,Inhibition of 5HT3 receptor,CHEMBL1139735,IC50,COC(=O)c1c(-c2ccc(F)cc2)c(-c2ccncc2)c(N2CCNCC2)n1C
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,9.4,nM,CHEMBL947384,B,Displacement of radiolabeled MDL 72222 from human 5HT3 receptor,CHEMBL1140203,IC50,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL470432,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,6.918,nM,CHEMBL964023,B,Displacement of [3H]granisetron from human recombinant 5HT3 receptor,CHEMBL1153939,IC50,CCCN1CCC(COc2nc3scc(C)c3n3cccc23)CC1
CHEMBL54720,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.413,nM,CHEMBL963183,B,Displacement of [3H]granisetron form 5HT3 receptor in hybrid NG180-15 cells,CHEMBL1153939,IC50,c1ccc(CN2CCN(c3nc4ccsc4n4cccc34)CC2)cc1
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,10.0,nM,CHEMBL983898,B,Inhibition of human 5HT3 receptor,CHEMBL1155111,IC50,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL1163015,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2800.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)NCCN(C)CC1CCCCC1(O)c1cccc(O)c1
CHEMBL572038,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3500.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)CCNC(=O)c2cc(Cl)c(N)cc2OC)c1
CHEMBL584743,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4900.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cccc([C@]2(O)CCCC[C@H]2CN(C)CCNC(=O)c2cc(Cl)c(N)cc2OC)c1
CHEMBL569357,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3100.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)NCCN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL572248,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2500.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)NCCN(C)C[C@@H]1CCCC[C@@]1(O)c1cccc(O)c1
CHEMBL1748,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1600.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)NC1CCNCC1OC
CHEMBL583681,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2800.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cccc([C@@]2(O)CCCC[C@@H]2CN2CC[C@@H](NC(=O)c3cc(Cl)c(N)cc3OC)[C@@H](OC)C2)c1
CHEMBL570710,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1600.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(C[C@H]2CCCC[C@]2(O)c2cccc(O)c2)C[C@@H]1OC
CHEMBL569585,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,790.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cccc([C@@]2(O)CCCC[C@@H]2CN2CC[C@H](NC(=O)c3cc(Cl)c(N)cc3OC)[C@H](OC)C2)c1
CHEMBL585925,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,390.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(C[C@H]2CCCC[C@]2(O)c2cccc(O)c2)C[C@H]1OC
CHEMBL570487,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1700.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cccc([C@]2(O)CCCC[C@H]2CN2CC[C@H](NC(=O)c3cc(Cl)c(N)cc3OC)[C@H](OC)C2)c1
CHEMBL585567,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,18.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(C[C@@H]2CCCC[C@@]2(O)c2cccc(O)c2)C[C@H]1OC
CHEMBL571799,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,159.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cccc([C@]2(O)CCCC[C@H]2CN2CC[C@@H](NC(=O)c3cc(Cl)c(N)cc3OC)[C@@H](OC)C2)c1
CHEMBL572249,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1400.0,nM,CHEMBL1048157,B,Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(C[C@@H]2CCCC[C@@]2(O)c2cccc(O)c2)C[C@@H]1OC
CHEMBL1278088,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,8.9,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCCC2
CHEMBL1278087,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,15.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Cc1cccc2c(=O)n(N)c(CCCCN3CCN(c4ccc5ccccc5n4)CC3)nc12
CHEMBL1276922,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,22.1,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,CC(=O)N1CCc2c(sc3nc(CCCCN4CCN(c5ccc6ccccc6n5)CC4)n(N)c(=O)c23)C1
CHEMBL1277006,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,24.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,O=c1[nH]c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c1CCCC2
CHEMBL1277559,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,26.7,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Cc1sc2nc(CCCCN3CCN(c4ccc5ccccc5n4)CC3)n(N)c(=O)c2c1C
CHEMBL1277099,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,41.4,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(SCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2sc3c(c2c1=O)CCCC3
CHEMBL1277187,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,44.2,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,O=c1[nH]c(SCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2sc3c(c12)CCCC3
CHEMBL1277996,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,45.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Cc1ccc2nc(CCCCN3CCN(c4ccc5ccccc5n4)CC3)n(N)c(=O)c2c1
CHEMBL1277651,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,45.7,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2ccccc2c1=O
CHEMBL1276921,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,46.5,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CC(O)CC2
CHEMBL1278175,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,48.3,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,CC1CCc2nc(CCCCN3CCN(c4ccc5ccccc5n4)CC3)n(N)c(=O)c2C1
CHEMBL1276832,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,48.4,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Cc1sc2nc(SCCCN3CCN(c4ccc5ccccc5n4)CC3)n(N)c(=O)c2c1C
CHEMBL1276833,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,50.5,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Cc1sc2nc(SCCCN3CCN(c4cc(C)c5ccccc5n4)CC3)n(N)c(=O)c2c1C
CHEMBL1277652,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,50.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2cccc(F)c2c1=O
CHEMBL1277282,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,52.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3nc4ccccc4cc3O)CC2)nc2c(c1=O)CCCC2
CHEMBL1277373,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,55.2,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccc(O)cc4n3)CC2)nc2c(c1=O)CCCC2
CHEMBL1277007,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,59.1,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Cc1cc(N2CCN(CCCCc3nc4c(c(=O)n3N)CCCC4)CC2)nc2ccccc12
CHEMBL1277372,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,61.0,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(SCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2cccnc2c1=O
CHEMBL1276834,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,62.1,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCC2
CHEMBL1277281,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,63.8,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(SCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCCC2
CHEMBL1277462,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,64.8,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(SCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2ncccc2c1=O
CHEMBL1277280,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,69.9,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(SCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2ccccc2c1=O
CHEMBL1277558,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,77.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,CC(=O)N1CCc2c(sc3nc(SCCCN4CCN(c5ccc6ccccc6n5)CC4)n(N)c(=O)c23)C1
CHEMBL1277914,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,83.1,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(Cl)cccc2c1=O
CHEMBL1276835,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,84.8,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCCCC2
CHEMBL1277374,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,86.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCCC2
CHEMBL1276920,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,87.6,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Cc1sc2nc(SCCCN3CCN(c4nc5ccccc5s4)CC3)n(N)c(=O)c2c1C
CHEMBL1278176,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,97.9,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,CC1CCc2c(nc(CCCCN3CCN(c4ccc5ccccc5n4)CC3)n(N)c2=O)C1
CHEMBL1277745,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,99.4,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2ccc(F)cc2c1=O
CHEMBL1277463,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,100.0,nM,CHEMBL1286079,B,Displacement of [3H]BRL-43694 from human 5HT3 receptor expressed in HEK293 cells by liquid scintillation counting,CHEMBL1275331,IC50,Nn1c(SCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2sc3c(c2c1=O)CCNC3
CHEMBL1770373,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2300.0,nM,CHEMBL1772905,B,Binding affinity to 5-HT3 receptor,CHEMBL1770110,IC50,c1ccc(Cc2ncc3c(n2)CCNCC3)cc1
CHEMBL378349,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,188.0,nM,CHEMBL2157806,B,Inhibition of 5HT3 receptor,CHEMBL2151039,IC50,O=C(N[C@H]1CN2CCC1CC2)c1ccc2ccsc2c1
CHEMBL379302,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,962.0,nM,CHEMBL2157806,B,Inhibition of 5HT3 receptor,CHEMBL2151039,IC50,O=C(N[C@H]1CN2CCC1CC2)c1ccc2ccoc2c1
CHEMBL378471,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,580.0,nM,CHEMBL2157806,B,Inhibition of 5HT3 receptor,CHEMBL2151039,IC50,O=C(N[C@H]1CN2CCC1CC2)c1ccc2occc2c1
CHEMBL597241,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,484.0,nM,CHEMBL2157806,B,Inhibition of 5HT3 receptor,CHEMBL2151039,IC50,Clc1cnc2nc(N3CCN4CCC3CC4)oc2c1
CHEMBL603052,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,70.0,nM,CHEMBL2157806,B,Inhibition of 5HT3 receptor,CHEMBL2151039,IC50,Cc1nc2nc(N3CCN4CCC3CC4)oc2cc1Cl
CHEMBL2151572,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,299.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,IC50,O=C(N[C@H]1CN2CCC1CC2)c1cc2cccc(Cl)c2s1
CHEMBL2332488,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,19000.0,nM,CHEMBL2340862,B,Inhibition of 5HT3 receptor (unknown origin),CHEMBL2331502,IC50,CN(C)CCCn1c(=O)c(C#N)c(-c2ccccc2)c2ccccc21
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4.9,nM,CHEMBL2394823,B,Binding affinity to human 5-HT3 receptor by radioligand displacement assay,CHEMBL2390917,IC50,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,11.0,nM,CHEMBL2395076,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEK293 cells after 60 mins,CHEMBL2390918,IC50,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,6.7,nM,CHEMBL2394926,B,Binding affinity to human 5-HT3 receptor by radioligand displacement assay,CHEMBL2390830,IC50,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.3,nM,CHEMBL3097165,B,Antagonist activity at human 5-HT3A receptor D165K mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.02,nM,CHEMBL3097167,B,Antagonist activity at human 5-HT3A receptor S163T mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.57,nM,CHEMBL3097168,B,Antagonist activity at human 5-HT3A receptor S163A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4.4,nM,CHEMBL3097170,B,Antagonist activity at human 5-HT3A receptor F130A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.64,nM,CHEMBL3097172,B,Antagonist activity at human 5-HT3A receptor Y73S mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.23,nM,CHEMBL3097173,B,Antagonist activity at human 5-HT3A receptor Y73F mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,13.1,nM,CHEMBL3097174,B,Antagonist activity at human 5-HT3A receptor Y73A mutant assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.83,nM,CHEMBL3097175,B,Antagonist activity at human wild type 5-HT3A receptor expressed in HEK293 cells assessed as inhibition of 5-HT-induced response after 45 mins by FLIPR assay,CHEMBL3091286,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1365455,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,6.9,nM,CHEMBL3779748,B,Displacement of [3H]BRL43694 from human recombinant 5-HT3 receptor expressed in CHO cells,CHEMBL3774372,IC50,CN1[C@@H]2CC[C@H]1CC(OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL3909084,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1600.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)nccc2c1
CHEMBL3918431,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,480.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1
CHEMBL3946303,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4200.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Cn1cnc2cnc(NC3=NC[C@@]4(CN5CCC4CC5)O3)cc21
CHEMBL3909492,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Cn1cnc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc21
CHEMBL3937435,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,54.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1cc2occc2c(NC2=NC[C@@]3(CN4CCC3CC4)O2)n1
CHEMBL3900472,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,690.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1nc(NC2=NC[C@@]3(CN4CCC3CC4)O2)c2ccsc2n1
CHEMBL3928422,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,50.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1nc(NC2=NC[C@@]3(CN4CCC3CC4)O2)c2sccc2n1
CHEMBL3891441,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,86000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Cn1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnc21
CHEMBL3969845,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,250.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1cn2nc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ccc2n1
CHEMBL3917985,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,7.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Clc1cnn2ccc(NC3=NC[C@@]4(CN5CCC4CC5)O3)nc12
CHEMBL3963469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,5.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1cc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)nccn2c1
CHEMBL3951684,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,12000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Brc1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)nccn12
CHEMBL3901366,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,7.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Cc1cn2cccc2c(NC2=NC[C@@]3(CN4CCC3CC4)O2)n1
CHEMBL3957600,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,35.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1cc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn2c1
CHEMBL3897030,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,34000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Brc1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn12
CHEMBL3961124,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,29000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Clc1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn12
CHEMBL3905979,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,320.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Fc1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn12
CHEMBL3907100,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,71000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Cc1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn12
CHEMBL3931382,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,19000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,N#Cc1ccc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn12
CHEMBL3980345,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2200.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Brc1cc2c(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncnn2c1
CHEMBL3910223,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,5600.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Brc1ccn2ncnc(NC3=NC[C@@]4(CN5CCC4CC5)O3)c12
CHEMBL3891068,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,28000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Brc1cc(Br)n2ncnc(NC3=NC[C@@]4(CN5CCC4CC5)O3)c12
CHEMBL3919130,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,87000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Clc1ccc2c(NC3=NC[C@]4(CN5CCC4CC5)O3)ncnn12
CHEMBL3900048,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,170.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Clc1ccc2c(NC3=NC4(CO3)CN3CCC4CC3)ncnn12
CHEMBL3928032,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,61000.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,Clc1ccc2c(NC3=NCCC4(CN5CCC4CC5)O3)ncnn12
CHEMBL3909099,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,180.0,nM,CHEMBL3871229,B,Antagonist activity at 5-HT3A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of Ca2+ flux by Fluo-4-AM dye based FLIPR assay,CHEMBL3870365,IC50,c1cc2c(NC3=NC[C@@]4(CN5CC[C@@H]4C5)O3)ncnn2c1
CHEMBL3963788,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1600.0,nM,CHEMBL3874726,B,Displacement of [3H] GR-65630 from recombinant human 5-HT3 receptor expressed in HEK293 cells,CHEMBL3872258,IC50,Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)F)cc3)c(N)c2c1C
CHEMBL3942511,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1500.0,nM,CHEMBL3874726,B,Displacement of [3H] GR-65630 from recombinant human 5-HT3 receptor expressed in HEK293 cells,CHEMBL3872258,IC50,Cc1nnc2sc(C(=O)NCc3ccc(S(F)(F)(F)(F)F)cc3)c(N)c2c1C
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,6.9,nM,CHEMBL3876395,B,Displacement of [3H]BRL 43694 from human recombinant 5HT3 receptor expressed in CHO cells measured after 120 mins by scintillation counting method,CHEMBL3875185,IC50,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL3953315,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.13,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(CC(F)(F)F)c3ccc(F)cc13)C2
CHEMBL3918054,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.4,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1nn(S(C)(=O)=O)c3ccccc13)C2
CHEMBL3979379,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.49,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(NC(=O)c1nn(CC(F)F)c3ccccc13)C2
CHEMBL3923484,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.57,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CC(C)S(=O)(=O)n1cc(C(=O)NC2CC3COCC(C2)N3C)c2ccccc21
CHEMBL3925843,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.93,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1c(Cl)n(S(C)(=O)=O)c3ccccc13)C2
CHEMBL3984661,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.25,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1nn(CCF)c3ccccc13)C2
CHEMBL3913903,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,7.72,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CS(=O)(=O)n1cc(C(=O)OC2CC3COCC(C2)N3)c2cc(F)ccc21
CHEMBL4114119,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.13,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn([C@@H](F)C(F)(F)F)c3ncccc13)C2
CHEMBL3947651,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.54,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(S(C)(=O)=O)c3ccccc13)C2
CHEMBL3904155,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.95,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(C3CCOC3)c3ccc(F)cc13)C2
CHEMBL3942335,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.38,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(CC(F)(F)F)c3ccc(F)cc13)C2
CHEMBL3927586,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.54,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)(F)F)c3ccc(F)cc13)C2
CHEMBL3902773,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.82,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(NC1CC2COCC(C1)N2)c1cn(CC(F)(F)F)c2ncccc12
CHEMBL3925327,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,5.56,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(CC(F)(F)F)c3ncccc13)C2
CHEMBL3923015,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.87,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1c(Cl)n(CC(F)(F)F)c3ccccc13)C2
CHEMBL3956338,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.33,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(S(C)(=O)=O)c3ccccc13)C2
CHEMBL3962958,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,13.0,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2CCF)c1cn(CC(F)(F)F)c2ccc(F)cc12
CHEMBL3929838,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.05,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(C(F)(F)C(F)F)c3ncc(F)cc13)C2
CHEMBL3920436,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.53,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(CCF)c3ccccc13)C2
CHEMBL3956912,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.36,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(CC(F)(F)F)c2ccc(F)cc12
CHEMBL3947167,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.75,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(NC(=O)c1nn(S(C)(=O)=O)c3ccccc13)C2
CHEMBL3940685,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4.09,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(NC1CC2COCC(C1)N2)c1nn(CC(F)F)c2ccccc12
CHEMBL3986850,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.95,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)F)c3ncc(F)cc13)C2
CHEMBL3955543,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.42,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(NC(=O)c1cn(S(C)(=O)=O)c3ccccc13)C2
CHEMBL3896879,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,10.5,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(NC(=O)c1cn(CC(F)F)c3ncccc13)C2
CHEMBL3919487,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.03,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(C(F)(F)C(F)F)c3ncccc13)C2
CHEMBL4111059,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.04,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn([C@@H]3CCOC3)c3ccccc13)C2
CHEMBL3894914,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.48,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(S(C)(=O)=O)c3ccc(F)cc13)C2
CHEMBL3911488,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.66,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1cn(CC(F)(F)F)c3ccc(F)cc13)C2
CHEMBL3893418,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.39,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CC(C)S(=O)(=O)n1cc(C(=O)NC2CC3COCC(C2)N3C)c2cc(F)ccc21
CHEMBL3929209,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.45,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn([C@H]3CCOC3)c3ccc(F)cc13)C2
CHEMBL3938530,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,12.79,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(NC(=O)c1cn(S(C)(=O)=O)c3ccc(F)cc13)C2
CHEMBL3981422,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,8.2,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1cn(CC(F)(F)F)c3ncccc13)C2
CHEMBL3896008,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.1,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3ncccn3)c3ccccc13)C2
CHEMBL3979389,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.23,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)F)c3ccccc13)C2
CHEMBL3951304,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.86,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3nccs3)c3ccccc13)C2
CHEMBL3896008,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.01,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3ncccn3)c3ccccc13)C2
CHEMBL3891400,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.22,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CCF)c3ccccc13)C2
CHEMBL3921737,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.55,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cnccn3)c3ccccc13)C2
CHEMBL3936101,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.5,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CCS(=O)(=O)n1cc(C(=O)OC2CC3COCC(C2)N3)c2ccccc21
CHEMBL3959461,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.914,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2cccnn2)c2ccccc12
CHEMBL3917810,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.9457,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(CC#N)c3c(F)nccc13)C2
CHEMBL3933042,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.71,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2ccsn2)c2ccccc12
CHEMBL3948391,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.4,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cncs3)c3ncccc13)C2
CHEMBL3968902,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.26,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2ccns2)c2ccccc12
CHEMBL3966488,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.746,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(CCF)c3ccc(C#N)cc13)C2
CHEMBL3943065,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.81,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cscn3)c3ncc(F)cc13)C2
CHEMBL3985721,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.165,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,Cn1ccc(-n2cc(C(=O)OC3CC4COCC(C3)N4)c3ccccc32)cc1=O
CHEMBL3896919,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.105,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,N#Cc1ccccc1-n1cc(C(=O)OC2CC3COCC(C2)N3)c2ccccc21
CHEMBL3895877,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,5.914,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,N#Cc1ccc(-n2cc(C(=O)OC3CC4COCC(C3)N4)c3ccccc32)cc1
CHEMBL3951841,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.27,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3cncs3)c3ccccc13)C2
CHEMBL3928579,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.5,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN(C(=O)c1cn(-c2cnsc2)c2ccccc12)C1CC2COCC(C1)N2C
CHEMBL3891620,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.46,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3cncnc3)c3ccccc13)C2
CHEMBL4112254,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.71,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn([C@@H]3CCOC3)c3ccc(F)cc13)C2
CHEMBL3984294,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.35,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)(F)F)c3ncccc13)C2
CHEMBL3904293,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.68,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)(F)F)c3ccccc13)C2
CHEMBL3894276,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.71,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2CCC(C1)N2)c1cn(CC(F)(F)F)c2ccccc12
CHEMBL3977239,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4.39,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1nn(CC(F)(F)F)c3ccccc13)C2
CHEMBL3941887,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.4,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1nn(CC(F)F)c3ccccc13)C2
CHEMBL3892459,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.06,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)(F)F)c3ncc(F)cc13)C2
CHEMBL3919866,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.89,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(CC(F)F)c3ccc(F)cc13)C2
CHEMBL3933362,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.2,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1c(Cl)n(CCF)c3ccccc13)C2
CHEMBL3910917,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,14.41,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2CCF)c1cn(CC(F)F)c2ccc(F)cc12
CHEMBL3984877,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.5,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(S(C)(=O)=O)c3ccc(F)cc13)C2
CHEMBL3930754,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,24.1,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(NC1CC2COCC(C1)N2)c1cn(CC(F)F)c2ncc(F)cc12
CHEMBL3986091,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.94,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(C3CCOC3)c3ccccc13)C2
CHEMBL3947310,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.09,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2CCC(C1)N2)c1cn(CC(F)F)c2ccccc12
CHEMBL3973732,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.84,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(CC(F)F)c3ncccc13)C2
CHEMBL3935292,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.6,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(CCF)c3ncccc13)C2
CHEMBL3945299,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,5.61,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CC(C)S(=O)(=O)n1cc(C(=O)OC2CC3COCC(C2)N3)c2cc(F)ccc21
CHEMBL3934819,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.44,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1cn(CC(F)F)c3ccc(F)cc13)C2
CHEMBL3973304,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.49,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)F)c3ccc(F)cc13)C2
CHEMBL3930983,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.07,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1nn(CC(F)F)c3ncccc13)C2
CHEMBL3906341,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.06,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(C(C)(C)C(F)(F)F)c3ncccc13)C2
CHEMBL3915317,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.59,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(CC(F)F)c3ncccc13)C2
CHEMBL3895387,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.15,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(NC(=O)c1cn(CC(F)F)c3ccc(F)cc13)C2
CHEMBL3928064,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4.81,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CS(=O)(=O)n1cc(C(=O)NC2CC3COCC(C2)N3)c2cc(F)ccc21
CHEMBL3946404,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.44,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(C(F)C(F)(F)F)c3ncccc13)C2
CHEMBL3960290,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.64,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1c3n(c4ccccc14)CCCCO3)C2
CHEMBL3916920,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.18,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1cn(CCF)c3ccccc13)C2
CHEMBL3939459,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.75,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(NC(=O)c1nn(CC(F)F)c3ccccc13)C2
CHEMBL3925926,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.89,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(CC(F)(F)F)c3ccccc13)C2
CHEMBL3914825,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,5.45,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(NC(=O)c1cn(CC(F)F)c3ccc(F)cc13)C2
CHEMBL3932951,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.05,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(C)(F)F)c3ncccc13)C2
CHEMBL3923484,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.77,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CC(C)S(=O)(=O)n1cc(C(=O)NC2CC3COCC(C2)N3C)c2ccccc21
CHEMBL3929017,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.4,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cncs3)c3ccccc13)C2
CHEMBL3923591,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.28,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cccnn3)c3ccccc13)C2
CHEMBL3949515,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.16,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2nccs2)c2ccccc12
CHEMBL3978355,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.93,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CC(C)S(=O)(=O)n1cc(C(=O)OC2CC3COCC(C2)N3)c2ccccc21
CHEMBL3894667,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.99,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(S(=O)(=O)C2CC2)c2ccccc12
CHEMBL3984660,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.681,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3ccc(F)nn3)c3ccccc13)C2
CHEMBL3938528,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.4155,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2cnsc2)c2ccccc12
CHEMBL3960503,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.702,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3nccs3)c3ncccc13)C2
CHEMBL3909661,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.87,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3ccsn3)c3ccccc13)C2
CHEMBL3894103,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.36,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3ccns3)c3ccccc13)C2
CHEMBL3915089,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.179,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cncs3)c3ncc(F)cc13)C2
CHEMBL3962464,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.5975,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3ccc(O)nn3)c3ccccc13)C2
CHEMBL3973438,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.89,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,N#Cc1cccc(-n2cc(C(=O)OC3CC4COCC(C3)N4)c3ccccc32)c1
CHEMBL3984662,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.219,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2ncco2)c2ccccc12
CHEMBL3923885,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.1,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3cnccn3)c3ccccc13)C2
CHEMBL3934011,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.25,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3cnc(F)cn3)c3ccccc13)C2
CHEMBL3897074,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.18,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,N#CCn1cc(C(=O)OC2CC3COCC(C2)N3)c2ccccc21
CHEMBL3909570,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.75,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3ccnnc3)c3ccccc13)C2
CHEMBL3960233,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.03,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,Cc1c(C(=O)OC2CC3CCC(C2)N3C)c2ccccc2n1S(C)(=O)=O
CHEMBL3909121,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.33,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(NC1CC2COCC(C1)N2)c1cn(CC(F)(F)F)c2ccc(F)cc12
CHEMBL3978355,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.8,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CC(C)S(=O)(=O)n1cc(C(=O)OC2CC3COCC(C2)N3)c2ccccc21
CHEMBL3895498,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.45,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(NC(=O)c1nn(CCF)c3ccccc13)C2
CHEMBL3956047,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.53,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,Cc1c(C(=O)OC2CC3CCC(C2)N3C)c2ccccc2n1CCF
CHEMBL3895876,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4.06,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(NC(=O)c1cn(S(C)(=O)=O)c3ccc(F)cc13)C2
CHEMBL3982898,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.4,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(NC1CC2COCC(C1)N2)c1cn(CC(F)F)c2ccccc12
CHEMBL3920451,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.88,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2ncccn2)c2ccccc12
CHEMBL3928641,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.08,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1c3n(c4ccccc14)CCO3)C2
CHEMBL3905347,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.29,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(CC(F)F)c2ccc(F)cc12
CHEMBL3955200,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.74,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1cn(S(C)(=O)=O)c3ccc(F)cc13)C2
CHEMBL3893818,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.78,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn(CC(F)F)c3ccccc13)C2
CHEMBL3916337,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.02,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1c(Cl)n(CC(F)F)c3ccccc13)C2
CHEMBL3981749,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.59,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(NC(=O)c1nn(S(C)(=O)=O)c3ccccc13)C2
CHEMBL3944258,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.82,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(CC(F)(F)F)c3ncccc13)C2
CHEMBL3892459,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.05,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)(F)F)c3ncc(F)cc13)C2
CHEMBL3920932,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.9,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1c(Cl)n(CCF)c3ccccc13)C2
CHEMBL3900767,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.24,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(CC(F)F)c3ccc(F)cc13)C2
CHEMBL3962329,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.0,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCCC1CC(OC(=O)c1cn(CC(F)F)c3ncccc13)C2
CHEMBL3912693,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.43,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)F)c3ncccc13)C2
CHEMBL3943285,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.13,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn([C@H](F)C(F)(F)F)c3ncccc13)C2
CHEMBL3980976,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.15,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,Cc1c(C(=O)OC2CC3CCC(C2)N3C)c2ccccc2n1CC(F)F
CHEMBL3966678,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.22,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(NC(=O)c1cn(CC(F)F)c3ncccc13)C2
CHEMBL3891400,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.41,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CCF)c3ccccc13)C2
CHEMBL3960386,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.04,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1c3n(c4ccccc14)CCCO3)C2
CHEMBL3948240,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.22,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,Cc1c(C(=O)OC2CC3CCCC(C2)N3C)c2ccccc2n1CCF
CHEMBL3905810,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.83,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2CCC1CC(OC(=O)c1cn([C@H]3CCOC3)c3ccccc13)C2
CHEMBL3968090,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.29,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(S(C)(=O)=O)c3ccc(F)cc13)C2
CHEMBL3920500,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,34.13,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(NC1CC2COCC(C1)N2)c1cn(CC(F)(F)F)c2ncc(F)cc12
CHEMBL3986850,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.11,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)F)c3ncc(F)cc13)C2
CHEMBL3904293,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.53,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC(F)(F)F)c3ccccc13)C2
CHEMBL3923591,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.39,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cccnn3)c3ccccc13)C2
CHEMBL3960051,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.39,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cncnc3)c3ccccc13)C2
CHEMBL3958157,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.86,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1nn(CC(F)(F)F)c3ccccc13)C2
CHEMBL3921737,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.64,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cnccn3)c3ccccc13)C2
CHEMBL3965964,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.3,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CS(=O)(=O)n1cc(C(=O)OC2CC3COCC(C2)N3)c2ccccc21
CHEMBL3960181,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,11.7,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CC(C)CS(=O)(=O)n1cc(C(=O)OC2CC3COCC(C2)N3)c2ccccc21
CHEMBL3947319,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.119,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,O=C(OC1CC2COCC(C1)N2)c1cn(-c2cnccn2)c2ccccc12
CHEMBL3971611,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.61,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cnsc3)c3ccccc13)C2
CHEMBL3924093,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.4,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cscn3)c3ncccc13)C2
CHEMBL3979838,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.328,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3cncn3C)c3ccccc13)C2
CHEMBL3895177,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.2985,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(CC#N)c3ccccc13)C2
CHEMBL3971761,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.81,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3nccs3)c3ncc(F)cc13)C2
CHEMBL3957067,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.533,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1nn(-c3cncs3)c3ccccc13)C2
CHEMBL3902436,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.065,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3ccccc3)c3ccccc13)C2
CHEMBL3911435,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.027,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(NC(=O)c1cn(-c3ncco3)c3ccccc13)C2
CHEMBL3942973,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.62,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3ccsn3)c3ccccc13)C2
CHEMBL3906022,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.06,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN(C(=O)c1cn(-c2cnsc2)c2ccccc12)C1CC2COCC(C1)N2
CHEMBL3919672,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.75,nM,CHEMBL3888296,B,"In Vitro Inhibition of Ca Flux Assay: The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37 °C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37 °C. Growth media was removed and cells loaded with 200 uL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37 °C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10−7 through 10−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 uL was added to each well of the addition plate, 15 uL of 10× compound was also added to the addition plate, and finally 120 uL of HBSS/20 mM HEPES (for a total of 150 uL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 uL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 uL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886642,IC50,CN1C2COCC1CC(OC(=O)c1cn(-c3ncccn3)c3ccccc13)C2
CHEMBL3963201,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.95,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,O=C(O[C@H]1C[C@H]2COC[C@@H](C1)N2)c1cn(-c2ccncc2)c2ccccc12
CHEMBL3890437,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.51,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3cccnc3)c3ccccc13)C2
CHEMBL3914905,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.96,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccccn3)c3ccccc13)C2
CHEMBL3976639,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.69,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccncc3)c3ccccc13)C2
CHEMBL3905913,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.62,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,O=C(O[C@H]1C[C@H]2COC[C@@H](C1)N2)c1cn(-c2cccnc2)c2ccccc12
CHEMBL3890437,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.1,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3cccnc3)c3ccccc13)C2
CHEMBL3892769,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.86,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](OC(=O)c1cn(-c3ccccn3)c3ccccc13)C2
CHEMBL3914905,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.81,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccccn3)c3ccccc13)C2
CHEMBL3973885,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.68,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,Cn1cc(-n2cc(C(=O)O[C@H]3C[C@H]4COC[C@@H](C3)N4)c3ccccc32)cn1
CHEMBL3911935,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.65,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccccn3)c3ncccc13)C2
CHEMBL3978812,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.6,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3cccnc3)c3ncccc13)C2
CHEMBL3917359,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.8825,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccccn3)c3ncc(F)cc13)C2
CHEMBL3987099,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.72,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3cccnc3)c3ncc(F)cc13)C2
CHEMBL3926346,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.34,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1nn(-c3ccccn3)c3ccccc13)C2
CHEMBL3901835,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.662,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3cnn(C)c3)c3ccccc13)C2
CHEMBL3963431,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.5,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,Cn1ccc(-n2cc(C(=O)O[C@H]3C[C@H]4COC[C@@H](C3)N4)c3ccccc32)n1
CHEMBL3950406,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.75,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccn(C)n3)c3ccccc13)C2
CHEMBL3936610,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.013,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](OC(=O)c1cn(-c3cnn(CCF)c3)c3ccccc13)C2
CHEMBL3966403,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,3.68,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,N#Cc1cc(-n2cc(C(=O)O[C@H]3C[C@H]4COC[C@@H](C3)N4)c3ccccc32)ccn1
CHEMBL3942077,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.5,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,Cc1ncccc1-n1cc(C(=O)N[C@H]2C[C@H]3COC[C@@H](C2)N3C)c2ccccc21
CHEMBL3974896,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.1,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,Cc1ccncc1-n1cc(C(=O)N[C@H]2C[C@H]3COC[C@@H](C2)N3C)c2ccccc21
CHEMBL3950793,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.65,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,Cn1nccc1-n1cc(C(=O)O[C@H]2C[C@H]3COC[C@@H](C2)N3)c2ccccc21
CHEMBL3979768,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.01,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccnn3C)c3ccccc13)C2
CHEMBL3935377,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.39,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3cnn(C(F)F)c3)c3ccccc13)C2
CHEMBL3959374,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.2,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](OC(=O)c1cn(-c3cnn(C)c3)c3ccccc13)C2
CHEMBL3944338,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.44,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,O=C(N[C@H]1C[C@H]2COC[C@@H](C1)N2)c1cn(-c2cccnc2)c2ccccc12
CHEMBL3973788,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2.04,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,Cn1cc(-n2cc(C(=O)N[C@H]3C[C@H]4COC[C@@H](C3)N4)c3ccccc32)cn1
CHEMBL3944903,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.462,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](OC(=O)c1cn(-c3cn[nH]c3)c3ccccc13)C2
CHEMBL3920493,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,0.745,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,O=C(N[C@H]1C[C@H]2COC[C@@H](C1)N2)c1cn(-c2cn[nH]c2)c2ccccc12
CHEMBL3936092,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.36,nM,CHEMBL3888524,B,"Ca Flux Activity Assay: The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux activity of 3HT3a receptor expressed in HEK-293T cells. HEK-293T cells were transfected with the 5-HT3a expression construct using Xtreme Gene 9 (Roche) in 150 mm tissue culture treated plates and incubated for 24 hours at 37° C. Cells were then split and plated at a density of 60K cells/well in poly-lysine coated, black 96-well plates with clear bottoms (BD BioSciences) and incubated overnight at 37° C. Growth media was removed and cells loaded with 200 μL calcium indicator dye in HBSS containing 20 mM HEPES (Calcium 5 Assay kit, Molecular Devices) and incubated at 37° C. for 1 hour. While cells were incubating, the 10× antagonist and agonist/antagonist addition plates were made. For 10× antagonist plate: half log serial dilutions (final concentrations range from 10^−7 through 10^−10 with the bottom well a negative, no ligand control) were made from test compounds in DMSO at a 1000× concentration and then diluted to 10× in HBSS/20 mM HEPES. For addition plate: 5HT was diluted to 100× in HBSS/20 mM HEPES (final concentration in the assay−216 nM) and 15 μL was added to each well of the addition plate, 15 μL of 10× compound was also added to the addition plate, and finally 120 μL of HBSS/20 mM HEPES (for a total of 150 μL). Cells were then removed from the incubator and equilibrated to room temperature for 10 minutes, then 22.5 μL of 10× test compounds were added in triplicate to the plates and incubated at room temperature for 10 minutes (Tropisetron was used as a positive control in every assay). Test plate and addition plate were loaded into the FlexStation III (Molecular Devices), and using the fluidics, 22.5 μL compound additions were made (at t=~17 seconds), and fluorescence was measured for 90 seconds, reading every 2.2 seconds.",CHEMBL3886747,IC50,CN1[C@@H]2COC[C@H]1C[C@@H](NC(=O)c1cn(-c3ccc[n+]([O-])c3)c3ccccc13)C2
CHEMBL4105038,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,18000.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Clc1ccc2nc(NC3=NCC4(CN5CCC4CC5)N3)sc2c1
CHEMBL4080813,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,26.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,c1ccc2sc(NC3=NCC4(CN5CCC4CC5)N3)nc2c1
CHEMBL4086223,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,7400.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Cc1ccc2nc(NC3=NCC4(CN5CCC4CC5)N3)oc2c1
CHEMBL4104136,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,26.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,c1ccc2oc(NC3=NCC4(CN5CCC4CC5)N3)nc2c1
CHEMBL4078355,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,38000.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Clc1ccc2c(NC3=NCC4(CN5CCC4CC5)N3)ncnn12
CHEMBL4096397,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,14500.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,c1ccc2c(NC3=NCC4(CN5CCC4CC5)N3)ncnc2c1
CHEMBL4076554,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1400.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,c1ccc2nc(NC3=NCC4(CN5CCC4CC5)N3)cnc2c1
CHEMBL4077127,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,6400.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,c1cn(-c2cc(NC3=NCC4(CN5CCC4CC5)N3)ncn2)cn1
CHEMBL4093984,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,5600.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Clc1cnc(NC2=NCC3(CN4CCC3CC4)N2)cn1
CHEMBL4077622,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,620.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Clc1cnc(NC2=NCC3(CN4CCC3CC4)N2)nc1
CHEMBL4081582,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,860.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Clc1ccc(NC2=NCC3(CN4CCC3CC4)N2)nc1
CHEMBL4082605,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,13000.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,CN1C(Nc2nc3ccc(Cl)nc3s2)=NCC12CN1CCC2CC1
CHEMBL4060728,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,43.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,CN1C(Nc2nc3ccccc3s2)=NCC12CN1CCC2CC1
CHEMBL4063687,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,38.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Clc1cccc2sc(NC3=NCC4(CN5CCC4CC5)N3)nc12
CHEMBL4085299,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,51.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,COc1ccc2sc(NC3=NCC4(CN5CCC4CC5)N3)nc2c1
CHEMBL4067446,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,32000.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,Clc1ccc2nc(NC3=NCC4(CN5CCC4CC5)N3)sc2n1
CHEMBL4088682,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,32000.0,nM,CHEMBL4042648,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as decrease in calcium influx by Fluo-4-AM dye based FLIPR assay,CHEMBL4041530,IC50,COc1ccc2nc(NC3=NCC4(CN5CCC4CC5)N3)sc2c1
CHEMBL4128926,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4.9,nM,CHEMBL4121502,B,Displacement of [3H]BRL 43694 from human recombinant 5-HT3 receptor after 120 mins by scintillation counting analysis,CHEMBL4118122,IC50,CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12
CHEMBL25306,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,141253.75,nM,CHEMBL4219559,B,Inhibition of human 5-HT3A receptor expressed in Xenopus laevis oocytes assessed as HT-induced current by electrophysiological method,CHEMBL4219030,IC50,C=CC(C)(O)CCC=C(C)C
CHEMBL485259,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,257039.58,nM,CHEMBL4219559,B,Inhibition of human 5-HT3A receptor expressed in Xenopus laevis oocytes assessed as HT-induced current by electrophysiological method,CHEMBL4219030,IC50,CC12CCC(CC1)C(C)(C)O2
CHEMBL1382868,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,620.0,nM,CHEMBL4219555,B,Inhibition of human 5-HT3A receptor expressed in transient A201 cells after 30 mins by Fluo-4-AM dye based FLIPR assay,CHEMBL4219030,IC50,c1ccc2c(CSc3[nH]cnc4ncnc3-4)cccc2c1
CHEMBL4228983,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,150.0,nM,CHEMBL4219553,B,Inhibition of recombinant human 5-HT3A receptor expressed in HEK293 cell membranes using 5-HT as substrate in presence of [3H]GR65630,CHEMBL4219030,IC50,O=C(N[C@H]1CN2CCC1CC2)c1ccc2ncccc2c1
CHEMBL4225157,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1400.0,nM,CHEMBL4219545,B,Antagonist activity at 5-HT3A receptor (unknown origin) assessed as inhibition of serotonin-induced peak currents,CHEMBL4219030,IC50,C#CCNc1nc(NCCCCC2CCN(Cc3ccccc3)CC2)c(C#N)cc1C#N
CHEMBL4453847,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,710.0,nM,CHEMBL4408516,B,Antagonist activity at human 5-HT3A receptor expressed in Xenopus laevis oocytes at -90 mV holding potential in presence of serotonin by two-electrode voltage clamp method,CHEMBL4406831,IC50,O=C(N[C@H]1CN2CCC1CC2)c1cc2ccc3ccccc3n2c1
CHEMBL4468363,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,17.5,nM,CHEMBL4415155,B,Antagonist activity at 5-HT3 receptor (unknown origin),CHEMBL4414553,IC50,O=C(NC1CN2CCC1CC2)c1cc(Cl)cn2ccnc12
CHEMBL4797517,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,57.0,nM,CHEMBL4767116,B,Displacement of [3H]BRL 43694 from human recombinant 5-HT3 receptor after 120 mins by scintillation counting analysis,CHEMBL4765239,IC50,CN1CCN(c2nc3ncc(Cl)cc3n3cnnc23)CC1
CHEMBL4867565,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,67.6,nM,CHEMBL4844538,B,Antagonist activity at human 5-HT3 receptor expressed in CHO-K1 cells assessed as inhibition of 5-HT induced inward currents preincubated for 30 sec followed by 5HT addition for 2 sec at -60 mV holding potential by ion flux automated patch clamp assay,CHEMBL4842371,IC50,O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1.7,nM,CHEMBL4844538,B,Antagonist activity at human 5-HT3 receptor expressed in CHO-K1 cells assessed as inhibition of 5-HT induced inward currents preincubated for 30 sec followed by 5HT addition for 2 sec at -60 mV holding potential by ion flux automated patch clamp assay,CHEMBL4842371,IC50,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL5272946,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,224.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,O=C(N1CCN2CCC1CC2)n1nc(-c2ccc(F)cc2)c2c1COCC2
CHEMBL5278405,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,338.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,COc1ccc(-c2nn(C(=O)N3CCN4CCC3CC4)c3c2CCOC3)cc1
CHEMBL5273314,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1590.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,O=C(N1CCN2CCC1CC2)n1nc(-c2ccc(C(F)(F)F)cc2)c2c1COCC2
CHEMBL5288633,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,4210.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,CC1(C)Cc2c(c(-c3ccc(F)cc3)nn2C(=O)N2CCN3CCC2CC3)CO1
CHEMBL5275403,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,1970.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,Cl.O=C(N1CCN2CCC1CC2)n1nc(-n2cc(C(F)(F)F)cn2)c2c1COCC2
CHEMBL5278640,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,585.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,O=C(N1CCN2CCC1CC2)n1nc(-n2cc(Cl)cn2)c2c1COCC2
CHEMBL5278676,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,7470.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,O=C(N1CCN2CCC1CC2)n1nc(-n2cc(C(F)(F)F)cn2)c2c1CCOC2
CHEMBL5286066,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2190.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,O=C(N1CCN2CCC1CC2)n1nc(-n2cc(C(F)(F)F)cn2)c2c1CCC2
CHEMBL5286071,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,IC50,=,2470.0,nM,CHEMBL5225971,B,Antagonist activity at human 5HT3A expressed in HEK293 cells incubated for 1 hr by FLIPR assay,CHEMBL5223177,IC50,O=C(N1CCN2CCC1CC2)n1nc(-n2cc(C(F)(F)F)cn2)c2c1[C@H]1C[C@H]1C2
CHEMBL145033,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.138,nM,CHEMBL619054,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,CHEMBL1128980,KI,CC(C)n1cnc2c(C(=O)N[C@@H]3CN4CCC3CC4)cc(Cl)cc21
CHEMBL145033,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,602.56,nM,CHEMBL618891,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,CHEMBL1128980,KI,CC(C)n1cnc2c(C(=O)N[C@@H]3CN4CCC3CC4)cc(Cl)cc21
CHEMBL145725,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.537,nM,CHEMBL619054,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,CHEMBL1128980,KI,CC(C)n1cnc2c(C(=O)N[C@H]3CN4CCC3CC4)cc(Cl)cc21
CHEMBL145725,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.1445,nM,CHEMBL618891,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,CHEMBL1128980,KI,CC(C)n1cnc2c(C(=O)N[C@H]3CN4CCC3CC4)cc(Cl)cc21
CHEMBL27846,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.012,nM,CHEMBL618891,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,CHEMBL1128980,KI,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2
CHEMBL142852,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL619054,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,CHEMBL1128980,KI,CC(C)n1cnc2c(C(=O)NC3CC4CCC(C3)N4C)cc(Cl)cc21
CHEMBL142852,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,19.95,nM,CHEMBL618891,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,CHEMBL1128980,KI,CC(C)n1cnc2c(C(=O)NC3CC4CCC(C3)N4C)cc(Cl)cc21
CHEMBL28992,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.182,nM,CHEMBL619054,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,CHEMBL1128980,KI,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CN2CCC1CC2
CHEMBL28992,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5011.87,nM,CHEMBL618891,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,CHEMBL1128980,KI,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CN2CCC1CC2
CHEMBL38465,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.8,nM,CHEMBL618149,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL1124975,KI,Cc1[nH]cnc1Cc1nc(-c2ccccc2)cs1
CHEMBL329179,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.94,nM,CHEMBL618149,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL1124975,KI,Cc1[nH]cnc1Cc1nc(-c2ccccc2F)cs1
CHEMBL290938,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.0,nM,CHEMBL618149,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL1124975,KI,Cc1[nH]cnc1Cc1nc(-c2c[nH]c3ccccc23)cs1
CHEMBL46,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,16.2,nM,CHEMBL618149,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL1124975,KI,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
CHEMBL421747,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL618149,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL1124975,KI,Cc1[nH]cnc1Cc1nc(-c2cccc3cccnc23)cs1
CHEMBL93919,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.42,nM,CHEMBL618149,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL1124975,KI,COc1ccccc1-c1csc(Cc2[nH]cnc2C)n1
CHEMBL56564,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.7,nM,CHEMBL618149,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,CHEMBL1124975,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2
CHEMBL266591,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1200.0,nM,CHEMBL872927,B,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,CHEMBL1133711,KI,Cc1[nH]c2ccc(O)cc2c1CCN
CHEMBL558226,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.2,nM,CHEMBL875094,B,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,CHEMBL1130509,KI,COc1cc(N)c(Cl)cc1C(=O)NC1C2CC3CN(C2)CC31.Cl
CHEMBL56564,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.7,nM,CHEMBL618152,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL1124976,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2
CHEMBL40260,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.3,nM,CHEMBL618152,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL1124976,KI,N=C(N)NCc1nc(-c2c[nH]c3ccccc23)cs1
CHEMBL34291,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,152.0,nM,CHEMBL618151,B,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,CHEMBL1144908,KI,COc1cc(N)c(Cl)cc1C(=O)NC[C@@H]1CCN2CCC[C@@H]12
CHEMBL18041,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.7,nM,CHEMBL618152,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL1124976,KI,COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2
CHEMBL46,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,16.0,nM,CHEMBL618152,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,CHEMBL1124976,KI,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
CHEMBL66918,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.69,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,Cc1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1
CHEMBL56900,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.36,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,c1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1
CHEMBL304534,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.96,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,c1ccc(CCCn2c(N3CCNCC3)nc3ccccc32)cc1
CHEMBL292066,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,19.21,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,c1ccc2[nH]c(N3CCNCC3)nc2c1
CHEMBL305582,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.43,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,c1ccc(CCn2c(N3CCNCC3)nc3ccccc32)cc1
CHEMBL302743,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.21,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,Fc1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1
CHEMBL63863,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.43,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,c1ccc2cc(Cn3c(N4CCNCC4)nc4ccccc43)ccc2c1
CHEMBL66692,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.42,nM,CHEMBL619058,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,KI,COc1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1
CHEMBL182721,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5248.07,nM,CHEMBL840091,B,Binding affinity against 5-Hydroxytryptamine 3 receptor,CHEMBL1137161,KI,c1ccc2c(N3CCN(CCc4ccc5c(c4)NCN5)CC3)cccc2c1
CHEMBL42,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,186.21,nM,CHEMBL840091,B,Binding affinity against 5-Hydroxytryptamine 3 receptor,CHEMBL1137161,KI,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
CHEMBL18772,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.7,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,c1ccc2nc(N3CCNCC3)ccc2c1
CHEMBL18772,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.981,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,c1ccc2nc(N3CCNCC3)ccc2c1
CHEMBL388212,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3100.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C1=C2CN3CC[C@@H]4[C@@H]5[C@H]([C@@H](OC1)N1c6ccccc6[C@@]67CCN8CC9=CCO[C@H]([C@@H]([C@H]16)[C@H]9C[C@H]87)N5c1ccccc1)[C@H]2C[C@@H]43
CHEMBL388212,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3162.28,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C1=C2CN3CC[C@@H]4[C@@H]5[C@H]([C@@H](OC1)N1c6ccccc6[C@@]67CCN8CC9=CCO[C@H]([C@@H]([C@H]16)[C@H]9C[C@H]87)N5c1ccccc1)[C@H]2C[C@@H]43
CHEMBL415570,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,O=[N+]([O-])c1ccc(C[N+]23CCC4[C@@H]5/C(=C\N6c7ccccc7[C@@]78CC[N+]9(Cc%10ccc([N+](=O)[O-])cc%10)CC%10=CCO[C@H]([C@@H]([C@H]67)[C@H]%10C[C@@H]89)N5c5ccccc5)[C@@H](C[C@@H]42)/C(=C\CO)C3)cc1.[Br-].[Br-]
CHEMBL415570,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,O=[N+]([O-])c1ccc(C[N+]23CCC4[C@@H]5/C(=C\N6c7ccccc7[C@@]78CC[N+]9(Cc%10ccc([N+](=O)[O-])cc%10)CC%10=CCO[C@H]([C@@H]([C@H]67)[C@H]%10C[C@@H]89)N5c5ccccc5)[C@@H](C[C@@H]42)/C(=C\CO)C3)cc1.[Br-].[Br-]
CHEMBL388049,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,COc1ccc(C[N+]23CC[C@@H]4[C@@H]5/C(=C\N6c7ccccc7[C@@]78CC[N+]9(Cc%10ccc(OC)c(OC)c%10)CC%10=CCO[C@H]([C@@H]([C@H]67)[C@H]%10C[C@@H]89)N5c5ccccc5)[C@@H](C[C@@H]42)/C(=C\CO)C3)cc1OC.[Cl-].[Cl-]
CHEMBL388049,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,COc1ccc(C[N+]23CC[C@@H]4[C@@H]5/C(=C\N6c7ccccc7[C@@]78CC[N+]9(Cc%10ccc(OC)c(OC)c%10)CC%10=CCO[C@H]([C@@H]([C@H]67)[C@H]%10C[C@@H]89)N5c5ccccc5)[C@@H](C[C@@H]42)/C(=C\CO)C3)cc1OC.[Cl-].[Cl-]
CHEMBL415569,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,40000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,OC/C=C1/C[N+]2(C3C=CCCC3)CC[C@@H]3[C@@H]4/C(=C\N5c6ccccc6[C@@]67CC[N+]8(C9C=CCCC9)CC9=CCO[C@H]([C@@H]([C@H]56)[C@H]9C[C@@H]78)N4c4ccccc4)[C@H]1C[C@@H]32.[Br-].[Br-]
CHEMBL415569,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,39810.72,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,OC/C=C1/C[N+]2(C3C=CCCC3)CC[C@@H]3[C@@H]4/C(=C\N5c6ccccc6[C@@]67CC[N+]8(C9C=CCCC9)CC9=CCO[C@H]([C@@H]([C@H]56)[C@H]9C[C@@H]78)N4c4ccccc4)[C@H]1C[C@@H]32.[Br-].[Br-]
CHEMBL415568,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5900.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C[N+]12CC[C@@H]3[C@@H]4/C(=C\N5c6ccccc6[C@@]67CC[N+]8(C)CC9=CCO[C@H]([C@@H]([C@H]56)[C@H]9C[C@@H]78)N4c4ccccc4)[C@@H](C[C@@H]31)/C(=C\CO)C2.[I-].[I-]
CHEMBL415568,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6309.57,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C[N+]12CC[C@@H]3[C@@H]4/C(=C\N5c6ccccc6[C@@]67CC[N+]8(C)CC9=CCO[C@H]([C@@H]([C@H]56)[C@H]9C[C@@H]78)N4c4ccccc4)[C@@H](C[C@@H]31)/C(=C\CO)C2.[I-].[I-]
CHEMBL388048,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1900.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,OC/C=C1/CN2CC[C@H]3[C@@H]2C[C@@H]1/C1=C/N2c4ccccc4[C@@]45CCN6CC7=CCO[C@H]([C@@H]([C@H]24)[C@H]7C[C@H]65)N(c2ccccc2)[C@@H]13
CHEMBL388048,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1995.26,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,OC/C=C1/CN2CC[C@H]3[C@@H]2C[C@@H]1/C1=C/N2c4ccccc4[C@@]45CCN6CC7=CCO[C@H]([C@@H]([C@H]24)[C@H]7C[C@H]65)N(c2ccccc2)[C@@H]13
CHEMBL229998,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,23000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,O=[N+]([O-])c1ccc(C[N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(Cc7ccc([N+](=O)[O-])cc7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)cc1.[Br-].[Br-]
CHEMBL229998,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,25118.86,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,O=[N+]([O-])c1ccc(C[N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(Cc7ccc([N+](=O)[O-])cc7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)cc1.[Br-].[Br-]
CHEMBL388046,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5700.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,Brc1ccc(C[N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(Cc7ccc(Br)cc7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)cc1.[Br-].[Br-]
CHEMBL388046,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6309.57,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,Brc1ccc(C[N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(Cc7ccc(Br)cc7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)cc1.[Br-].[Br-]
CHEMBL389120,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,28000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,COc1ccc(C[N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(Cc7ccc(OC)c(OC)c7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)cc1OC.[Cl-].[Cl-]
CHEMBL389120,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,25118.86,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,COc1ccc(C[N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(Cc7ccc(OC)c(OC)c7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)cc1OC.[Cl-].[Cl-]
CHEMBL396705,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C1=C2C[N+]3(Cc4ccccc4)CC[C@@H]4[C@@H]5[C@H]([C@@H](OC1)N1c6ccccc6[C@@]67CC[N+]8(Cc9ccccc9)CC9=CCO[C@H]([C@@H]([C@H]16)[C@H]9C[C@@H]78)N5c1ccccc1)[C@H]2C[C@@H]43.[Br-].[Br-]
CHEMBL396705,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C1=C2C[N+]3(Cc4ccccc4)CC[C@@H]4[C@@H]5[C@H]([C@@H](OC1)N1c6ccccc6[C@@]67CC[N+]8(Cc9ccccc9)CC9=CCO[C@H]([C@@H]([C@H]16)[C@H]9C[C@@H]78)N5c1ccccc1)[C@H]2C[C@@H]43.[Br-].[Br-]
CHEMBL231056,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2700.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C1=CC([N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(C7C=CCCC7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)CCC1.[Br-].[Br-]
CHEMBL231056,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2511.89,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C1=CC([N+]23CC[C@@H]4[C@@H]5[C@@H]6[C@@H](OCC=C(C2)[C@@H]6C[C@@H]43)N2c3ccccc3[C@@]34CC[N+]6(C7C=CCCC7)CC7=CCO[C@H]([C@@H]([C@H]23)[C@H]7C[C@@H]46)N5c2ccccc2)CCC1.[Br-].[Br-]
CHEMBL230952,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,15000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C/C=C/C[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CC[N+]5(C/C=C/C)CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@@H]35)N4c1ccccc1.[Br-].[Br-]
CHEMBL230952,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,15848.93,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C/C=C/C[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CC[N+]5(C/C=C/C)CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@@H]35)N4c1ccccc1.[Br-].[Br-]
CHEMBL390135,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C=CC[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CC[N+]5(CC=C)CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@@H]35)N4c1ccccc1.[Br-].[Br-]
CHEMBL390135,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C=CC[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CC[N+]5(CC=C)CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@@H]35)N4c1ccccc1.[Br-].[Br-]
CHEMBL244561,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,19000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C=CC[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CCN5CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@H]53)N4c1ccccc1.[Br-]
CHEMBL244561,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,19952.62,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C=CC[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CCN5CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@H]53)N4c1ccccc1.[Br-]
CHEMBL395727,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,11000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CC[N+]5(C)CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@@H]35)N4c1ccccc1.[I-].[I-]
CHEMBL395727,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,10000.0,nM,CHEMBL896285,B,Displacement of [3H]GR65630 from human 5HT3A receptor in HEK293 cells,CHEMBL1148788,KI,C[N+]12CC[C@@H]3[C@@H]4[C@@H]5[C@@H](OCC=C(C1)[C@@H]5C[C@@H]32)N1c2ccccc2[C@@]23CC[N+]5(C)CC6=CCO[C@H]([C@@H]([C@H]12)[C@H]6C[C@@H]35)N4c1ccccc1.[I-].[I-]
CHEMBL15056,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.33,nM,CHEMBL945897,B,Binding affinity to 5HT3 receptor,CHEMBL1141467,KI,c1ccc2c(NCCc3ccc(OCCCN4CCCCC4)cc3)c3c(nc2c1)CCCC3
CHEMBL195241,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.6,nM,CHEMBL945897,B,Binding affinity to 5HT3 receptor,CHEMBL1141467,KI,Cc1c(N2CCN(C)CC2)nc2ccccc2c1C(=O)NCCCCCCCNc1c2c(nc3ccccc13)CCCC2
CHEMBL401541,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1051.0,nM,CHEMBL930822,B,Binding affinity to human 5HT3 receptor,CHEMBL1141581,KI,NC1=Nc2cccc(Cl)c2CN1
CHEMBL1548,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,172.0,nM,CHEMBL930822,B,Binding affinity to human 5HT3 receptor,CHEMBL1141581,KI,NC1=Nc2ccc(Cl)c(Cl)c2CN1
CHEMBL404372,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1062.3,nM,CHEMBL930106,B,Binding affinity to human 5HT3 receptor,CHEMBL1141640,KI,C[C@@H]1NC(N)=Nc2cccc(Cl)c21
CHEMBL526307,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000000.0,nM,CHEMBL960847,B,Inhibition of 5HT3 receptor,CHEMBL1153301,KI,COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1I
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6.6,nM,CHEMBL947384,B,Displacement of radiolabeled MDL 72222 from human 5HT3 receptor,CHEMBL1140203,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL68131,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,158.49,nM,CHEMBL964233,B,Binding affinity at 5HT3 receptor,CHEMBL1153939,KI,CCCCN1CCC(COC(=O)c2cc(Cl)c(N)c3c2OCCO3)CC1
CHEMBL117287,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3981.07,nM,CHEMBL964233,B,Binding affinity at 5HT3 receptor,CHEMBL1153939,KI,COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1
CHEMBL56564,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.818,nM,CHEMBL964233,B,Binding affinity at 5HT3 receptor,CHEMBL1153939,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2
CHEMBL3084582,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,316.23,nM,CHEMBL964233,B,Binding affinity at 5HT3 receptor,CHEMBL1153939,KI,COc1ccc2[nH]c(=O)n(C(=O)N[C@@H]3C[C@H]4CC[C@@H](C3)N4C)c2c1
CHEMBL287045,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,125.89,nM,CHEMBL964233,B,Binding affinity at 5HT3 receptor,CHEMBL1153939,KI,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC
CHEMBL472219,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,251.19,nM,CHEMBL964233,B,Binding affinity at 5HT3 receptor,CHEMBL1153939,KI,C[C@@]12CCCN1CC[C@H]2CNC(=O)c1cc(Cl)cc2nc[nH]c12
CHEMBL83954,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1995.26,nM,CHEMBL964233,B,Binding affinity at 5HT3 receptor,CHEMBL1153939,KI,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1
CHEMBL453996,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,311.0,nM,CHEMBL954297,B,Displacement of [3H]granisetron from human 5HT3 receptor expressed in HEK293 cells,CHEMBL1153958,KI,c1ccc2cc(OCC3CCNCC3)ccc2c1
CHEMBL444985,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,404.0,nM,CHEMBL954297,B,Displacement of [3H]granisetron from human 5HT3 receptor expressed in HEK293 cells,CHEMBL1153958,KI,N#Cc1ccc2ccc(OCC3CCNCC3)cc2c1
CHEMBL62023,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL993920,B,Binding affinity to 5HT3 receptor,CHEMBL1143324,KI,CCn1c(=O)n(C(=O)NC2CC3CCC(C2)N3C)c2ccccc21
CHEMBL565547,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3700.0,nM,CHEMBL1041012,B,Inhibition of 5HT3 receptor,CHEMBL1155340,KI,Cc1nc2c3c(nc(Cc4ccccc4)n2n1)CCNCC3
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.45,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL596951,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.17,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3cccc(O)c13)C2
CHEMBL596952,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,26.3,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,COc1cccc2c1c(C(=O)NC1C[C@@H]3CCC[C@@H](C1)N3C)nn2C
CHEMBL598803,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,375.0,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3cccc(OCc4ccccc4)c13)C2
CHEMBL598804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.3,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3ccc(O)cc13)C2
CHEMBL605562,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5306.0,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,COc1ccc2c(c1)c(C(=O)NC1C[C@@H]3CCC[C@@H](C1)N3C)nn2C
CHEMBL598805,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3029.0,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3ccc(OCc4ccccc4)cc13)C2
CHEMBL603673,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,279.0,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3cc(O)ccc13)C2
CHEMBL596758,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,237.0,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,COc1ccc2c(C(=O)NC3C[C@@H]4CCC[C@@H](C3)N4C)nn(C)c2c1
CHEMBL604083,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,749.0,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3cc(OCc4ccccc4)ccc13)C2
CHEMBL599011,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.67,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3c(O)cccc13)C2
CHEMBL599012,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,71.1,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,COc1cccc2c(C(=O)NC3C[C@@H]4CCC[C@@H](C3)N4C)nn(C)c12
CHEMBL605772,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.23,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@H]2CCC[C@H]1CC(NC(=O)c1nn(C)c3c(OCc4ccccc4)cccc13)C2
CHEMBL597984,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,59.3,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,Cn1nc(C(=O)NC2C[C@@H]3CCC[C@@H](C2)N3Cc2ccccc2)c2ccccc21
CHEMBL2309589,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.89,nM,CHEMBL1065651,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,CHEMBL1157568,KI,CN1[C@@H]2CCC[C@H]1C[C@@H](NC(=O)c1nn(CCCN)c3ccccc13)C2
CHEMBL3084719,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.8,nM,CHEMBL1065652,B,Binding affinity to human 5HT3A receptor in HEK293 cells assessed as cell labeling by confocal microscopy,CHEMBL1157568,KI,Cc1cc(C)n2c1C=C1C=CC(NCC(=O)NCCCn3nc(C(=O)N[C@H]4C[C@H]5CCC[C@@H](C4)N5C)c4ccccc43)=[N+]1[B-]2(F)F
CHEMBL1224527,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,870000.0,nM,CHEMBL1226123,B,Binding affinity to 5HT3 receptor,CHEMBL1221364,KI,Oc1ccc2c(c1O)C[C@@H](c1ccccc1)[C@@H]1CCNC[C@@H]21
CHEMBL1258223,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1072.0,nM,CHEMBL1259763,B,Binding affinity to human 5-HT3 receptor,CHEMBL1255169,KI,CCCCN1CCC(COC(=O)c2cc(Cl)c(NC)c3c2OCCO3)CC1
CHEMBL1258452,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3511.0,nM,CHEMBL1259763,B,Binding affinity to human 5-HT3 receptor,CHEMBL1255169,KI,CCCCN1CCC(COC(=O)c2ccc(N)c(OC)c2)CC1
CHEMBL3084779,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,15.1,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(-c4ccccc4)nc13)C2
CHEMBL3084780,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,16.3,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(-c4ccc(F)cc4)nc13)C2
CHEMBL3084781,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,18.0,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(-c4ccc(Cl)cc4)nc13)C2
CHEMBL3084782,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,18.8,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,COc1ccc(-c2nc3c(C(=O)N[C@@H]4C[C@H]5CCC[C@@H](C4)N5C)cccc3o2)cc1
CHEMBL3084783,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,40.4,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3nc(-c4ccccc4)oc13)C2
CHEMBL3084784,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,94.9,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3nc(-c4ccc(F)cc4)oc13)C2
CHEMBL3084759,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,73.8,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3nc(-c4ccc(Cl)cc4)oc13)C2
CHEMBL3084760,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,58.5,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,COc1ccc(-c2nc3cccc(C(=O)N[C@@H]4C[C@H]5CCC[C@@H](C4)N5C)c3o2)cc1
CHEMBL3084761,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,40.0,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(N4CCOCC4)nc13)C2
CHEMBL1271520,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,165.0,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(N3CCOCC3)nc12
CHEMBL3084762,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.9,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@H]1COCCN1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084763,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,92.6,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@@H]1COCCN1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084764,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.6,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CC[C@H]1COCCN1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084765,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.9,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CCC[C@H]1COCCN1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084766,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.0,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CC(C)[C@H]1COCCN1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084767,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.5,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CC(C)C[C@H]1COCCN1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084768,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(N4CCOC[C@@H]4C(C)(C)C)nc13)C2
CHEMBL3084769,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.6,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@H]1COC[C@H](C)N1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL1271790,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6.8,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@H]1COC[C@H](C)N1c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL3084770,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CC[C@H]1COC[C@H](C)N1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084771,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,35.3,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@@H]1CN(c2nc3c(C(=O)N[C@@H]4C[C@H]5CCC[C@@H](C4)N5C)cccc3o2)C[C@H](C)O1
CHEMBL3084772,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,72.2,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(N4CCNCC4)nc13)C2
CHEMBL3084773,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,16.5,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@H]1CNCCN1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084774,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,37.3,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@@H]1CNC[C@H](C)N1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084775,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,59.4,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@@H]1CNC[C@@H](C)N1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL3084776,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.4,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,C[C@H]1CNC[C@H](C)N1c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL1272016,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,47.3,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,COc1ccccc1-c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL3084777,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,14.9,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,COc1ccccc1-c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1
CHEMBL1272072,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,32.7,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(C3CC3)nc12
CHEMBL3084778,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.3,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1cccc3oc(C4CC4)nc13)C2
CHEMBL46,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.4,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
CHEMBL1110,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.5,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
CHEMBL1272122,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.4,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CCN(CC)c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL1272123,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,66.5,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CC(C)N(C)c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL1272176,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,18.2,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CN(C)c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL1272121,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,36.4,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CCNc1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL1272177,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,36.4,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,CNc1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL1272178,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.8,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,Nc1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1
CHEMBL1272232,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.7,nM,CHEMBL1274533,B,Binding affinity to human HT3A receptor,CHEMBL1268946,KI,Nc1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cc(Cl)cc2o1
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.981,nM,CHEMBL1285707,B,Binding affinity to 5HT3A receptor,CHEMBL1275268,KI,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.03162,nM,CHEMBL1285707,B,Binding affinity to 5HT3A receptor,CHEMBL1275268,KI,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1278088,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.72,nM,CHEMBL1286219,B,Binding affinity to human 5HT3 receptor,CHEMBL1275331,KI,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCCC2
CHEMBL1632158,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2511.89,nM,CHEMBL1640607,B,Binding affinity to 5HT3 receptor,CHEMBL1629440,KI,COC(=O)CCCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1
CHEMBL1643881,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.4,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,O=C1c2cccc3[nH]nc(c23)CN1[C@H]1CN2CCC1CC2
CHEMBL1643882,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.9,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,O=C1c2cccc3[nH]nc(c23)CN1[C@@H]1CN2CCC1CC2
CHEMBL1643883,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.7,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,Cn1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2
CHEMBL1643884,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.7,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,Cn1nc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)C2
CHEMBL1643885,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,Cn1nc2c3c(cc(F)cc31)C(=O)N([C@H]1CN3CCC1CC3)C2
CHEMBL1643886,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,CCn1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2
CHEMBL1643887,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.6,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,CCn1nc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)C2
CHEMBL1643888,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.6,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,CC(C)n1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2
CHEMBL1643889,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.3,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,CC(C)n1nc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)C2
CHEMBL1641625,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.4,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,CC(C)Cn1nc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)C2
CHEMBL1643890,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.1,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,O=C1c2cccc3c2c(nn3Cc2ccccc2)CN1[C@H]1CN2CCC1CC2
CHEMBL1643891,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,23.4,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,O=C1c2cccc3c2c(nn3-c2ccc(F)cc2)CN1[C@H]1CN2CCC1CC2
CHEMBL1643892,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.9,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,O=C1c2cccc3c2c(nn3-c2ccc(F)cc2)CN1[C@@H]1CN2CCC1CC2
CHEMBL1643893,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.9,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,Cn1cc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2
CHEMBL1643894,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.7,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,Cn1cc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)C2
CHEMBL1110,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.5,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
CHEMBL1643895,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.06,nM,CHEMBL1648623,B,Binding affinity to human 5HT3A receptor,CHEMBL1641372,KI,Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.9,nM,CHEMBL1817466,B,Displacement of [3H]BRL43694 from human 5HT3 receptor,CHEMBL1811872,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL27453,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,794.33,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,Clc1ccc(C2CCNC2)cc1
CHEMBL148204,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1000.0,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,Nc1ccc2cc3ccccc3nc2c1
CHEMBL1824047,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,794.33,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,N=C(N)NCCCc1ccccc1
CHEMBL260565,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,251.19,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,CN1CCN(c2ccc3cc(Cl)ccc3n2)CC1
CHEMBL414183,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.59,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,CN1CCN(c2nc3ccccc3nc2O)CC1
CHEMBL1824048,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.585,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,CN1CCC(=Cc2nc3cc(Cl)ccc3[nH]2)CC1
CHEMBL492884,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1258.93,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,CN1CCN(c2cc(-c3ccccc3)nc(N)n2)CC1
CHEMBL1824228,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1258.93,nM,CHEMBL1827026,B,Displacement of [3H]granisetron from human 5-HT3AR expressed in HEK293 cells after 24 hrs by liquid scintillation counting,CHEMBL1821608,KI,c1nc(CC2CCCCC2)c[nH]1
CHEMBL1834350,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,10000.0,nM,CHEMBL1839296,B,Inhibition of human 5-HT3 receptor,CHEMBL1833864,KI,CCN/C(=N\S(=O)(=O)c1cccc(Cl)c1)N1CC2(C=N1)CCNCC2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.45,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL3084430,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.9,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,COc1ccc(C2=[N+]3C(=Cc4c(C)c(CCC(=O)NCCCCCC(=O)NCCCn5nc(C(=O)N[C@@H]6C[C@H]7CCC[C@@H](C6)N7C)c6ccccc65)c(C)n4[B-]3(F)F)C=C2)cc1
CHEMBL3084431,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,199.0,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CCN(CC)c1ccc2cc(C(=O)NCCCn3nc(C(=O)N[C@@H]4C[C@H]5CCC[C@@H](C4)N5C)c4ccccc43)c(=O)oc2c1
CHEMBL3084432,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.6,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1nn(CCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)c3ccccc13)C2
CHEMBL3084433,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.3,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CCN(CC)c1ccc2cc(C(=O)NCCCCn3nc(C(=O)N[C@@H]4C[C@H]5CCC[C@@H](C4)N5C)c4ccccc43)c(=O)oc2c1
CHEMBL3084434,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.1,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1nn(CCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)c3ccccc13)C2
CHEMBL3084436,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,142.0,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CCN(CC)c1ccc2cc(C(=O)NCCOCCOCCn3nc(C(=O)N[C@@H]4C[C@H]5CCC[C@@H](C4)N5C)c4ccccc43)c(=O)oc2c1
CHEMBL3084437,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6300.0,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1nn(CCOCCOCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)c3ccccc13)C2
CHEMBL3084438,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.7,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CN1[C@@H]2CCC[C@H]1C[C@H](NC(=O)c1nn(CCCNc3ccc([N+](=O)[O-])c4nonc34)c3ccccc13)C2
CHEMBL3084439,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.2,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CN(C)c1cccc2c(S(=O)(=O)NCCCn3nc(C(=O)N[C@H]4C[C@H]5CCC[C@@H](C4)N5C)c4ccccc43)cccc12
CHEMBL3084440,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.6,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CC1=CC(C)=[N+]2C1=C(CCCOC(=O)CCCn1nc(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)c3ccccc31)c1c(C)cc(C)n1[B-]2(F)F
CHEMBL3084441,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.9,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CCN(CC)c1ccc2cc(C(=O)NCCOc3cccc4c(C(=O)N[C@@H]5C[C@H]6CCC[C@@H](C5)N6C)nn(C)c34)c(=O)oc2c1
CHEMBL3084442,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,157.0,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CCN(CC)c1ccc2cc(C(=O)NCCCOc3cccc4c(C(=O)N[C@H]5C[C@H]6CCC[C@@H](C5)N6C)nn(C)c34)c(=O)oc2c1
CHEMBL3084443,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1300.0,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CCN(CC)c1ccc2cc(C(=O)NCCOCCOCCOc3cccc4c(C(=O)N[C@@H]5C[C@H]6CCC[C@@H](C5)N6C)nn(C)c34)c(=O)oc2c1
CHEMBL3084444,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,208.0,nM,CHEMBL1948646,B,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,CHEMBL1944572,KI,CN1[C@@H]2CCC[C@H]1C[C@@H](NC(=O)c1nn(C)c3c(OCCOCCOCCNC(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)cccc13)C2
CHEMBL1829335,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1
CHEMBL1813065,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.8,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,C[C@@H]1CCCN1CCCOc1ccc(-c2cn[nH]c(=O)c2)cc1
CHEMBL1958132,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,19.0,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,O=c1cc(-c2ccc(OCCCN3CCCCC3)cc2)cn[nH]1
CHEMBL1958133,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.9,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,C[C@@H]1CCCN1CCCOc1ccc(-c2cnn(C)c(=O)c2)cc1
CHEMBL1958134,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.0,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cn1ncc(-c2ccc(OCCCN3CCCCC3)cc2)cc1=O
CHEMBL1958135,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.1,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cn1ncc(-c2ccc(OCCCN3CCCCCC3)cc2)cc1=O
CHEMBL1958322,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.7,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,CC(C)n1ncc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O
CHEMBL1958323,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.6,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1n[nH]c(=O)cc1-c1ccc(OCCCN2CCC[C@H]2C)cc1
CHEMBL1958324,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.9,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1n[nH]c(=O)cc1-c1ccc(OCCCN2CCCCC2)cc1
CHEMBL1958325,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.8,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1n[nH]c(=O)cc1-c1ccc(OCCCN2CCCCCC2)cc1
CHEMBL1958326,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1nn(C)c(=O)cc1-c1ccc(OCCCN2CCC[C@H]2C)cc1
CHEMBL1958327,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.9,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1nn(C)c(=O)cc1-c1ccc(OCCCN2CCCCC2)cc1
CHEMBL1945843,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.7,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,C[C@@H]1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1
CHEMBL1958328,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,11.0,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,C[C@H]1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1
CHEMBL1958329,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.8,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,O=c1cc(-c2ccc(OCCCN3CCCCC3)cc2)cnn1-c1ccccn1
CHEMBL1958330,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.3,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,O=c1cc(-c2ccc(OCCCN3CCCCCC3)cc2)cnn1-c1ccccn1
CHEMBL1958331,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.8,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1cccc(-n2ncc(-c3ccc(OCCCN4CCC[C@H]4C)cc3)cc2=O)n1
CHEMBL1958332,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.5,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1cccnc1-n1ncc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O
CHEMBL1958333,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.7,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1nn(-c2ccccn2)c(=O)cc1-c1ccc(OCCCN2CCC[C@H]2C)cc1
CHEMBL1958334,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.0,nM,CHEMBL1960084,B,Displacement of [3H]NAMH from human cloned 5HT3 receptor expressed in CHO cells,CHEMBL1955733,KI,Cc1cccnc1-n1nc(C)c(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O
CHEMBL2151443,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,150.0,nM,CHEMBL2157844,B,Displacement of [3H]-BRL-43694 from human 5HT3 receptor,CHEMBL2151039,KI,CN1CC2CN(c3ccc(-c4ccccc4)nn3)CC2C1
CHEMBL2151437,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.0,nM,CHEMBL2157811,B,Binding affinity to human 5HT3A receptor,CHEMBL2151039,KI,c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2
CHEMBL419496,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,O=C(N[C@H]1CN2CCC1CC2)c1cc(Cl)cc2c1OCC2
CHEMBL378349,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,174.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,O=C(N[C@H]1CN2CCC1CC2)c1ccc2ccsc2c1
CHEMBL379302,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,310.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,O=C(N[C@H]1CN2CCC1CC2)c1ccc2ccoc2c1
CHEMBL378471,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,663.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,O=C(N[C@H]1CN2CCC1CC2)c1ccc2occc2c1
CHEMBL2151439,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL2157806,B,Inhibition of 5HT3 receptor,CHEMBL2151039,KI,O=C(N[C@@H]1CN2CCC1CC2)c1n[nH]c2ccccc12
CHEMBL2151440,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,60.0,nM,CHEMBL2157688,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2151039,KI,COc1ccccc1-c1cccc2cc(C(=O)N[C@H]3CN4CCC3CC4)oc12
CHEMBL563848,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3993.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,O=C(Oc1ccccc1)N1CCN2CCC1CC2
CHEMBL597843,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,579.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,c1cnc2nc(N3CCN4CCC3CC4)oc2c1
CHEMBL611082,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,c1ccc2oc(N3CCN4CCC3CC4)nc2c1
CHEMBL597241,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1370.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,Clc1cnc2nc(N3CCN4CCC3CC4)oc2c1
CHEMBL603052,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,244.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KI,Cc1nc2nc(N3CCN4CCC3CC4)oc2cc1Cl
CHEMBL56564,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.3,nM,CHEMBL2157806,B,Inhibition of 5HT3 receptor,CHEMBL2151039,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2
CHEMBL2169974,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,331.13,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2ccc3cccc(N)c3n2)CC1
CHEMBL2169973,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,204.17,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2ccc3c(N)cccc3n2)CC1
CHEMBL2169972,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,218.78,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2cc3ccccc3c(N)n2)CC1
CHEMBL2169971,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.888,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(N2CCN(C)CC2)cc2ccccc12
CHEMBL2169970,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.445,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2cc(N)c3ccccc3n2)CC1
CHEMBL2169969,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.49,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1cc(N2CCN(C)CC2)nc2ccccc12
CHEMBL2169968,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,537.03,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2ccc3ccccc3c2)CC1
CHEMBL2169967,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,407.38,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2cnc3ccccc3c2)CC1
CHEMBL2169966,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.622,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2cc3ccccc3cn2)CC1
CHEMBL288591,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.4571,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2ccc3ccccc3n2)CC1
CHEMBL123137,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.677,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2cnc3ccccc3n2)CC1
CHEMBL2169965,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.951,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(N2CCN(C)CC2)nc2ccccc12
CHEMBL475331,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.05129,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(N)c3ccccc3n2)CC1
CHEMBL2169964,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,46.77,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc3ccccc3c(=O)[nH]2)CC1
CHEMBL443764,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.349,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2ncc3ccccc3n2)CC1
CHEMBL454890,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.818,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(NCc3ccoc3)c3cc(Cl)ccc3n2)CC1
CHEMBL489664,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,14.79,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(NCCO)c3cc(Cl)ccc3n2)CC1
CHEMBL489271,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.692,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(NCc3ccc(N)cc3)c3cc(Cl)ccc3n2)CC1
CHEMBL490072,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,79.43,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(NCCc3ccccc3)c3cc(Cl)ccc3n2)CC1
CHEMBL490071,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.8,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(NCc3ccccc3)c3cc(Cl)ccc3n2)CC1
CHEMBL489061,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,16595.87,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(NCC3CCCCC3)c3cc(Cl)ccc3n2)CC1
CHEMBL490073,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,165.96,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CC(C)Nc1nc(N2CCN(C)CC2)nc2ccc(Cl)cc12
CHEMBL489060,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6.607,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(N(C)C)c3cc(Cl)ccc3n2)CC1
CHEMBL473302,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.02,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(N)c3cc(Cl)ccc3n2)CC1
CHEMBL471712,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,575.44,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2nc(O)c3cc(Cl)ccc3n2)CC1
CHEMBL2169890,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.413,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CN1CCN(c2ncc3cc(Cl)ccc3n2)CC1
CHEMBL462417,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,11748.98,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(NCCC2CCN(C)C2)nc2ccc(Cl)cc12
CHEMBL461729,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3548.13,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(N2CC3CCCNC3C2)nc2ccc(Cl)cc12
CHEMBL461360,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2344.23,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(N2CC[C@H](N)C2)nc2ccc(Cl)cc12
CHEMBL2169975,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,467.74,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(N2CC(N(C)C)C2)nc2ccc(Cl)cc12
CHEMBL489062,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.122,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(N2CCN(C)CC2)nc2ccc(Cl)cc12
CHEMBL511699,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,18.2,nM,CHEMBL2174993,B,Displacement of [3H]granisetron from 5HT3A receptor expressed in HEK293 cells after 24 hrs by scintillation counting in presence of quipazine,CHEMBL2169766,KI,CNc1nc(N2CCCN(C)CC2)nc2ccc(Cl)cc12
CHEMBL2181188,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2470.0,nM,CHEMBL2188188,B,Binding affinity to human 5HT3 by Cerep protocol based assay,CHEMBL2176996,KI,CCCN1CCC(COc2nc3c(Cl)cccc3c3ccccc23)CC1
CHEMBL2181169,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1314.0,nM,CHEMBL2188188,B,Binding affinity to human 5HT3 by Cerep protocol based assay,CHEMBL2176996,KI,CCCN1CCC(COc2nc3c(I)cccc3c3ccccc23)CC1
CHEMBL2181189,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,710.0,nM,CHEMBL2188188,B,Binding affinity to human 5HT3 by Cerep protocol based assay,CHEMBL2176996,KI,CCCN1CCC(COc2nc3c(F)cccc3c3ccccc23)CC1
CHEMBL2181171,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,680.0,nM,CHEMBL2188188,B,Binding affinity to human 5HT3 by Cerep protocol based assay,CHEMBL2176996,KI,CCCN1CCC(COc2nc3ccccc3c3ncccc23)CC1
CHEMBL2181170,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,641.0,nM,CHEMBL2188188,B,Binding affinity to human 5HT3 by Cerep protocol based assay,CHEMBL2176996,KI,CCCN1CCC(COc2nc3c(F)cccc3c3ncccc23)CC1
CHEMBL2181166,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,410.0,nM,CHEMBL2188188,B,Binding affinity to human 5HT3 by Cerep protocol based assay,CHEMBL2176996,KI,Fc1cccc2c1nc(OCC1CCN(CCCc3ccc(I)cc3)CC1)c1cccnc12
CHEMBL2179529,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,700.0,nM,CHEMBL2184671,B,Inhibition of human 5HT3 receptor,CHEMBL2176988,KI,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1
CHEMBL365323,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,49.8,nM,CHEMBL2182409,B,Inhibition of human 5HT3R,CHEMBL2177097,KI,O=C(NC1CN2CCC1CC2)c1cc2ccccc2s1
CHEMBL2179862,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,18600.0,nM,CHEMBL2182409,B,Inhibition of human 5HT3R,CHEMBL2177097,KI,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2cn1
CHEMBL2205362,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7612.0,nM,CHEMBL2209488,B,Displacement of [3H]LY278584 from human recombinant 5-HT3 receptor after 1.5 hrs by scintillation counting analysis,CHEMBL2203183,KI,COc1cc2oc(C(=O)N(CCCN3CCCCC3)c3ccccc3)c(C)c2cc1OC
CHEMBL2205035,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,270.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Oc2ccccc2N2CCNCC2)c(C)c1.Cl
CHEMBL2205034,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,27.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2N2CCCNCC2)c(C)c1.Cl
CHEMBL2205033,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,130.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2N2CCN(C)CC2)c(C)c1.Cl
CHEMBL2205032,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,670.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2c(C)cccc2N2CCNCC2)c(C)c1.Cl
CHEMBL2205031,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,45.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2cc(C)ccc2N2CCNCC2)c(C)c1.Cl
CHEMBL2204365,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,150.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccc(C)cc2N2CCNCC2)c(C)c1.Cl
CHEMBL2204364,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,160.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2cccc(C)c2N2CCNCC2)c(C)c1.Cl
CHEMBL2204360,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.7,nM,CHEMBL2215840,B,Binding affinity to human 5HT3A receptor,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1.Cl
CHEMBL2204363,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.3,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1.Cl
CHEMBL2204362,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,17.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1cc(C)ccc1Sc1ccccc1N1CCNCC1.Cl
CHEMBL2204361,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1.Cl
CHEMBL2204360,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,23.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1.Cl
CHEMBL2204359,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,26.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1
CHEMBL2204358,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,32.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1ccc(Sc2ccccc2N2CCNCC2)c(OC)c1.Cl
CHEMBL2204357,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,29.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1cccc(Sc2ccccc2N2CCNCC2)c1C.Cl
CHEMBL2204356,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,67.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cl.Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl
CHEMBL2204355,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,80.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1cccc(Sc2ccccc2N2CCNCC2)c1OC.Cl
CHEMBL2205054,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,33.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C.Cl
CHEMBL2205053,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,110.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)cc1Cl
CHEMBL2205052,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,86.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1ccc(Sc2ccccc2N2CCNCC2)cc1OC.Cl
CHEMBL2205051,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,32.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccccc1Sc1ccccc1N1CCNCC1.Cl
CHEMBL2205050,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,52.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1ccccc1Sc1ccccc1N1CCNCC1.Cl
CHEMBL2205049,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,64.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1cccc(Sc2ccccc2N2CCNCC2)c1.Cl
CHEMBL2205048,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,62.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1cccc(Sc2ccccc2N2CCNCC2)c1.Cl
CHEMBL46,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.8,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
CHEMBL2205047,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,450.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,CC(C)(C)c1ccc(Sc2ccccc2N2CCNCC2)cc1.Cl
CHEMBL2205046,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,140.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cl.FC(F)(F)c1ccc(Sc2ccccc2N2CCNCC2)cc1
CHEMBL2205045,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,56.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1.Cl
CHEMBL2205044,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,53.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cl.Fc1ccc(Sc2ccccc2N2CCNCC2)cc1
CHEMBL2205043,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,36.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)cc1
CHEMBL2205042,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,36.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1ccc(Sc2ccccc2N2CCNCC2)cc1.Cl
CHEMBL2205041,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,64.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cl.c1ccc(Sc2ccccc2N2CCNCC2)cc1
CHEMBL2205040,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,260.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccc(C)cc2N2CCNCC2)cc1.Cl
CHEMBL2205039,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,440.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccc(F)cc2)c(N2CCNCC2)c1.Cl
CHEMBL2205038,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,500.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccc(Cl)cc2)c(N2CCNCC2)c1.Cl
CHEMBL2205037,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,190.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,COc1ccc(Sc2ccc(C)cc2N2CCNCC2)cc1.Cl
CHEMBL2205036,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,310.0,nM,CHEMBL2215843,B,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay,CHEMBL2203036,KI,Cc1ccc(Sc2ccccc2)c(N2CCNCC2)c1.Cl
CHEMBL42,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,186.21,nM,CHEMBL3073102,B,Binding affinity to 5-HT3 receptor (unknown origin),CHEMBL3046886,KI,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
CHEMBL2298806,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5248.07,nM,CHEMBL3073102,B,Binding affinity to 5-HT3 receptor (unknown origin),CHEMBL3046886,KI,c1ccc2c(N3CCN(CCc4ccc5[nH]cnc5c4)CC3)cccc2c1
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.5,nM,CHEMBL2395076,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEK293 cells after 60 mins,CHEMBL2390918,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL2107804,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.7,nM,CHEMBL2394926,B,Binding affinity to human 5-HT3 receptor by radioligand displacement assay,CHEMBL2390830,KI,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1cc(Cl)cc(Cl)c1)C2
CHEMBL481153,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1900.0,nM,CHEMBL2404434,B,Antagonist activity at serotonin 5HT3 receptor (unknown origin) by PDSP assay,CHEMBL2401658,KI,O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21
CHEMBL519609,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3900.0,nM,CHEMBL2404434,B,Antagonist activity at serotonin 5HT3 receptor (unknown origin) by PDSP assay,CHEMBL2401658,KI,CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21
CHEMBL1729,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1995.26,nM,CHEMBL2406742,B,Binding affinity to serotonin 5-HT3 receptor (unknown origin),CHEMBL2401700,KI,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
CHEMBL2401750,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(=O)N1CCC(CN2CCC(CNC(=O)c3cccc4[nH]c(C(C)C)nc34)CC2)CC1
CHEMBL2402904,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,COC(=O)N1CCC(CN2CCC(CNC(=O)c3cccc4[nH]c(C(C)C)nc34)CC2)CC1
CHEMBL2402903,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(C)c1nc2c(C(=O)NCC3CCN(CC4CCN(S(C)(=O)=O)CC4)CC3)cccc2[nH]1
CHEMBL2402902,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,63095.73,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(=O)N(C)CC(O)CN1CCC(CNC(=O)c2cccc3[nH]c(C(C)C)nc23)CC1
CHEMBL2402901,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,50118.72,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,COC(=O)N(C)CC(O)CN1CCC(CNC(=O)c2cccc3[nH]c(C(C)C)nc23)CC1
CHEMBL2402900,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,79432.82,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(C)c1nc2c(C(=O)NCC3CCN(CC(O)CN(C)S(C)(=O)=O)CC3)cccc2[nH]1
CHEMBL2402899,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,39810.72,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(=O)N1CCN(CCN2CCC(CNC(=O)c3cccc4[nH]c(C(C)C)nc34)CC2)CC1
CHEMBL2402898,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,79432.82,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,COC(=O)N1CCN(CCN2CCC(CNC(=O)c3cccc4[nH]c(C(C)C)nc34)CC2)CC1
CHEMBL2402897,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,100000.0,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(C)c1nc2c(C(=O)NCC3CCN(CCN4CCN(S(C)(=O)=O)CC4)CC3)cccc2[nH]1
CHEMBL2402896,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1258.93,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(C)c1nc2c(C(=O)NCC3CCN(CC(O)CN4CCN(S(C)(=O)=O)CC4)CC3)cc(Cl)cc2[nH]1
CHEMBL2402895,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,15848.93,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CS(=O)(=O)N1CCN(CC(O)CN2CCC(CNC(=O)c3cccc4[nH]c(-c5ccccc5)nc34)CC2)CC1
CHEMBL2402894,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7943.28,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(F)(F)c1nc2c(C(=O)NCC3CCN(CC(O)CN4CCN(S(C)(=O)=O)CC4)CC3)cccc2[nH]1
CHEMBL2402893,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,39810.72,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(C)(C)c1nc2c(C(=O)NCC3CCN(CC(O)CN4CCN(S(C)(=O)=O)CC4)CC3)cccc2[nH]1
CHEMBL2402892,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,50118.72,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CS(=O)(=O)N1CCN(CC(O)CN2CCC(CNC(=O)c3cccc4[nH]c(C5CC5)nc34)CC2)CC1
CHEMBL2402891,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,79432.82,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CC(C)c1nc2c(C(=O)NCC3CCN(CC(O)CN4CCN(S(C)(=O)=O)CC4)CC3)cccc2[nH]1
CHEMBL2402890,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,79432.82,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CCc1nc2c(C(=O)NCC3CCN(CC(O)CN4CCN(S(C)(=O)=O)CC4)CC3)cccc2[nH]1
CHEMBL76370,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2511.89,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12
CHEMBL1729,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1995.26,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
CHEMBL2402889,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,63095.73,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CS(=O)(=O)N1CCN(CC(O)CN2CCC(NC(=O)c3cccc4[nH]cnc34)CC2)CC1
CHEMBL2402888,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,19952.62,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CS(=O)(=O)N1CCN(CC(O)CN2[C@@H]3CC[C@H]2C[C@@H](NC(=O)c2cccc4[nH]cnc24)C3)CC1
CHEMBL2402887,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,50118.72,nM,CHEMBL2404383,B,Binding affinity to human recombinant 5HT3 receptor,CHEMBL2401700,KI,CS(=O)(=O)N1CCN(CC(O)CN2CCC(CNC(=O)c3cccc4[nH]cnc34)CC2)CC1
CHEMBL2431120,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1000.0,nM,CHEMBL2433833,B,Binding affinity to 5-HT3 receptor (unknown origin),CHEMBL2429761,KI,COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC
CHEMBL2436555,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,80.0,nM,CHEMBL2437595,B,Displacement of [3H]GR65630 from human 5-HT3 receptor expressed in African green monkey COS cells after 90 mins by scintillation counting analysis,CHEMBL2434905,KI,Cl.NC1=Nc2ccc(Cl)cc2CN1
CHEMBL2436555,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,34.0,nM,CHEMBL2437602,B,Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin) expressed in mouse/rat NG108-15 cells after 30 mins by by liquid scintillation counting analysis,CHEMBL2434905,KI,Cl.NC1=Nc2ccc(Cl)cc2CN1
CHEMBL13823,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,32.0,nM,CHEMBL2437602,B,Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin) expressed in mouse/rat NG108-15 cells after 30 mins by by liquid scintillation counting analysis,CHEMBL2434905,KI,N=C(N)Nc1cccc(Cl)c1
CHEMBL654,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2900.0,nM,CHEMBL2437603,B,Displacement of [3H]GR65630 from human 5-HT3A receptor expressed in HEK293 cells by liquid scintillation counting analysis,CHEMBL2434905,KI,CN1CCN2c3ncccc3Cc3ccccc3C2C1
CHEMBL2058416,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6178.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,C/N=C1\NC(=O)/C(=C\c2c[nH]c3ccc(Br)cc23)N1C
CHEMBL2058415,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5916.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,C/N=C1\NC(=O)/C(=C\c2c[nH]c3cccc(Br)c23)N1C
CHEMBL404232,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3029.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,CN1C(=N)N(C)/C(=C/c2c[nH]c3ccccc23)C1=O
CHEMBL2058427,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2624.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3ccc(Br)cc23)N1C
CHEMBL512332,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1511.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3ccccc23)N1C
CHEMBL2058420,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1223.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,CN1C(=N)N(C)/C(=C/c2c[nH]c3c(Br)cccc23)C1=O
CHEMBL1170237,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1000.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,CN1C(=N)N(C)/C(=C/c2c[nH]c3ccc(Br)cc23)C1=O
CHEMBL2058419,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,656.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,CN1C(=N)N(C)/C(=C/c2c[nH]c3cccc(Br)c23)C1=O
CHEMBL2058426,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,591.0,nM,CHEMBL2445944,B,Displacement of [3H]GR65630 from human recombinant 5HT3 receptor expressed in HEKT cells,CHEMBL2440075,KI,C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3cccc(Br)c23)N1C
CHEMBL3093187,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2600.0,nM,CHEMBL3094818,B,Binding affinity to human 5HT3,CHEMBL3091289,KI,Fc1cccc2c1nc(OCC1CCN(CCCC(F)(F)F)CC1)c1cccnc12
CHEMBL3093186,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1200.0,nM,CHEMBL3094818,B,Binding affinity to human 5HT3,CHEMBL3091289,KI,Fc1cccc2c1nc(OCC1CCN(CCC(F)(F)F)CC1)c1cccnc12
CHEMBL18041,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.3981,nM,CHEMBL3106134,B,Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin),CHEMBL3102773,KI,COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2
CHEMBL18041,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.39,nM,CHEMBL3106134,B,Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin),CHEMBL3102773,KI,COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2
CHEMBL3104093,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,529.0,nM,CHEMBL3106134,B,Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin),CHEMBL3102773,KI,CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1
CHEMBL3104093,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,501.19,nM,CHEMBL3106134,B,Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin),CHEMBL3102773,KI,CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1
CHEMBL479683,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2511.89,nM,CHEMBL3129965,B,Displacement of [3H]GR65630 from 5-HT3 receptor (unknown origin),CHEMBL3124907,KI,O=c1cc(CCc2ccccc2)oc2cccc(O)c12
CHEMBL715,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1000.0,nM,CHEMBL3226689,B,Binding affinity to serotonin 5-HT3 receptor (unknown origin) by PDSP assay,CHEMBL3217546,KI,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
CHEMBL42,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1000.0,nM,CHEMBL3226689,B,Binding affinity to serotonin 5-HT3 receptor (unknown origin) by PDSP assay,CHEMBL3217546,KI,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
CHEMBL1112,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1000.0,nM,CHEMBL3226689,B,Binding affinity to serotonin 5-HT3 receptor (unknown origin) by PDSP assay,CHEMBL3217546,KI,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
CHEMBL3217984,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,630.96,nM,CHEMBL3226689,B,Binding affinity to serotonin 5-HT3 receptor (unknown origin) by PDSP assay,CHEMBL3217546,KI,CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3
CHEMBL3235480,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,230.0,nM,CHEMBL3238702,B,Displacement of [3H]GR65630 from human 5-HT3 receptor expressed in HEK293 cells,CHEMBL3232832,KI,O=S1(=O)c2cc(N3CCN4CCC3CC4)ccc2-c2cccc(F)c21
CHEMBL3235482,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,505.0,nM,CHEMBL3238702,B,Displacement of [3H]GR65630 from human 5-HT3 receptor expressed in HEK293 cells,CHEMBL3232832,KI,O=S1(=O)c2ccc(F)cc2-c2ccc(N3CCN4CCC3CC4)cc21
CHEMBL3261478,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,67.6,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,O=C1c2cccc3ccn(c23)CCN1[C@H]1CN2CCC1CC2
CHEMBL3261479,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.1,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261480,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.2,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,Cc1cn2c3c(cc(Cl)cc13)C(=O)N([C@@H]1CN3CCC1CC3)CC2
CHEMBL3261481,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.1,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261482,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6.4,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,O=C1c2cc(F)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261483,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.5,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261484,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.8,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,Cc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1
CHEMBL3261485,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.5,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,COc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1
CHEMBL3261486,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.7,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261487,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,701.0,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,O=C1c2cccc3c2N(CCN1[C@@H]1CN2CCC1CC2)S(=O)(=O)N3
CHEMBL1110,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.5,nM,CHEMBL3268497,B,Displacement of [9-methyl-3H]BRL-43694 from human 5-HT3A receptor after overnight incubation by scintillation proximity assay,CHEMBL3259590,KI,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
CHEMBL177611,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,930.0,nM,CHEMBL3365595,B,Inhibition of 5-HT3 receptor (unknown origin),CHEMBL3352239,KI,O=C(N[C@H]1CN2CCC1CC2)c1ccc(Cl)cc1
CHEMBL3746146,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.0,nM,CHEMBL3748599,B,Displacement of [3H]BRL 43694 from human 5-HT3 receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL3745708,KI,COc1cccc(-c2cn([C@H]3CN4CCC3CC4)nn2)c1
CHEMBL3747344,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.0,nM,CHEMBL3748599,B,Displacement of [3H]BRL 43694 from human 5-HT3 receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL3745708,KI,c1cc2cc(-c3cn([C@H]4CN5CCC4CC5)nn3)ccc2o1
CHEMBL3746799,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,52.0,nM,CHEMBL3748599,B,Displacement of [3H]BRL 43694 from human 5-HT3 receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL3745708,KI,c1cc2cc(-c3cn(C4CN5CCC4CC5)nn3)ccc2[nH]1
CHEMBL523797,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3260.0,nM,CHEMBL3863913,B,Displacement of [3H]GR65630 from human 5-HT3 receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method,CHEMBL3862033,KI,O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NCc3cccc(Cl)c3)nc(Cl)nc21
CHEMBL1643894,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,Cn1cc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)C2
CHEMBL3679403,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CN1CC2CCCC1CC(N1Cc3cn(C)c4cccc(c34)C1=O)C2
CHEMBL3679393,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CN1Nc2cn([C@@H]3CN4CCC3CC4)c(=O)c3cccc1c23
CHEMBL3679398,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CC(C)N1Nc2cn([C@@H]3CN4CCC3CC4)c(=O)c3cccc1c23
CHEMBL3679396,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CCN1Nc2cn([C@@H]3CN4CCC3CC4)c(=O)c3cccc1c23
CHEMBL3679399,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CC(C)CN1Nc2cn([C@@H]3CN4CCC3CC4)c(=O)c3cccc1c23
CHEMBL3679402,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=c1c2cccc3c2c(cn1[C@@H]1CN2CCC1CC2)NN3c1ccc(F)cc1
CHEMBL3679392,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=c1c2cccc3c2c(cn1[C@@H]1CN2CCC1CC2)NN3
CHEMBL3679390,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CN1Nc2cn([C@H]3CN4CCC3CC4)c(=O)c3cccc1c23
CHEMBL3679394,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CN1Nc2cn([C@H]3CN4CCC3CC4)c(=O)c3cc(F)cc1c23
CHEMBL3679395,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CCN1Nc2cn([C@H]3CN4CCC3CC4)c(=O)c3cccc1c23
CHEMBL3679397,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CC(C)N1Nc2cn([C@H]3CN4CCC3CC4)c(=O)c3cccc1c23
CHEMBL3679391,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=c1c2cccc3c2c(cn1[C@H]1CN2CCC1CC2)NN3
CHEMBL3679400,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=c1c2cccc3c2c(cn1[C@H]1CN2CCC1CC2)NN3Cc1ccccc1
CHEMBL3679401,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,29.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=c1c2cccc3c2c(cn1[C@H]1CN2CCC1CC2)NN3c1ccc(F)cc1
CHEMBL3679404,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,68.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=c1c2cccc3c2c(cn1[C@H]1CN2CCC1CC2)NN3c1ccc(Cl)cc1
CHEMBL3679405,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,57.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,COc1ccc(N2Nc3cn([C@H]4CN5CCC4CC5)c(=O)c4cccc2c34)cc1
CHEMBL3679406,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=c1c2cc(Br)cc3c2c(cn1[C@H]1CN2CCC1CC2)NN3
CHEMBL3679407,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,34.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CN1Nc2cn(C3CC4CCCC(C3)N4C)c(=O)c3cccc1c23
CHEMBL3679408,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3[nH]nc(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3639782,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,Cn1nc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)CC2
CHEMBL3679409,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CCn1nc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)CC2
CHEMBL3679410,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CC(C)n1nc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)CC2
CHEMBL3679411,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3c2c(nn3Cc2ccccc2)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3679412,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,108.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3[nH]nc(c23)CCN1[C@H]1CN2CCC1CC2
CHEMBL3679408,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3[nH]nc(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3679420,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,25.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3c2c(cn3S(=O)(=O)c2ccccc2)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3679413,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,Cn1cc2c3c(cccc31)C(=O)N([C@@H]1CN3CCC1CC3)CC2
CHEMBL3679414,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3c2c(cn3Cc2ccccc2)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3679415,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,49.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3[nH]cc(c23)CCN1[C@H]1CN2CCC1CC2
CHEMBL3679416,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,Cn1cc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)CC2
CHEMBL3679417,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,13.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,O=C1c2cccc3c2c(cn3Cc2ccccc2)CCN1[C@H]1CN2CCC1CC2
CHEMBL3679418,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,267.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CN1C2CCCC1CC(N1CCc3cn(C)c4cccc(c34)C1=O)C2
CHEMBL3679419,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,59.0,nM,CHEMBL3705298,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format.",CHEMBL3638734,KI,CN1Nc2cn(C3CC4CCC(C3)N4C)c(=O)c3cccc1c23
CHEMBL3261478,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,74.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3ccn(c23)CCN1[C@H]1CN2CCC1CC2
CHEMBL3261479,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3673238,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,Cc1cn2c3c(cccc13)C(=O)N([C@@H]1CN3CCC1CC3)CC2
CHEMBL3261480,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.2,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,Cc1cn2c3c(cc(Cl)cc13)C(=O)N([C@@H]1CN3CCC1CC3)CC2
CHEMBL3673239,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,416.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3ccn(c23)CCCN1[C@H]1CN2CCC1CC2
CHEMBL3673240,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,205.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3ccn(c23)CCCN1[C@@H]1CN2CCC1CC2
CHEMBL3261481,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261483,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.5,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3673241,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cc(F)cc3cnn(c23)CCN1C1CN2CCC1CC2
CHEMBL3673242,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,14.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cc(CO)cc3cnn(c23)CCN1C1CN2CCC1CC2
CHEMBL3673243,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.8,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,Cc1cc2c3c(cnn3CCN(C3CN4CCC3CC4)C2=O)c1
CHEMBL3673244,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cc(O)cc3cnn(c23)CCN1C1CN2CCC1CC2
CHEMBL3673245,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,32.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3ncn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3673246,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,130.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,CCc1nc2cccc3c2n1CCN([C@@H]1CN2CCC1CC2)C3=O
CHEMBL3673247,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,406.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3nc(-c4ccccc4)n(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3673248,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,206.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3nc(-c4ccccc4Cl)n(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261486,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261487,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,701.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3c2N(CCN1[C@@H]1CN2CCC1CC2)S(=O)(=O)N3
CHEMBL3673249,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,8.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3c2c(cn3Cc2ccc(CO)cc2)CCN1CC12CCN(CC1)CC2
CHEMBL3673250,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,30.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3[nH]cc(c23)CCN1CC12CCN(CC1)CC2
CHEMBL3673251,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3[nH]nc(c23)CN1CC12CCN(CC1)CC2
CHEMBL3673252,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,217.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3[nH]nc(c23)CN1CC1CN2CCC1CC2
CHEMBL3673252,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,24.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3[nH]nc(c23)CN1CC1CN2CCC1CC2
CHEMBL3673253,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,73.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3cnn(c23)CCN1CC12CCN(CC1)CC2
CHEMBL3673254,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,579.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3[nH]nc(c23)CCN1CC1CN2CCC1CC2
CHEMBL3673254,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,241.0,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,O=C1c2cccc3[nH]nc(c23)CCN1CC1CN2CCC1CC2
CHEMBL1110,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.5,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
CHEMBL1643895,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.06,nM,CHEMBL3706294,B,"Radioligand Binding Assay: The relative affinity of the various compounds for the human 5-HT3 receptor was measured in a radioligand binding assay, using a scintillation proximity assay (SPA) format. Test compounds were dissolved to 10 mM in 100% DMSO, then serially diluted at 10x assay concentrations in 100% DMSO in 96-well polypropylene plates and further diluted to 4x assay concentrations with the assay buffer. Samples were incubated in 50 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 1 mM EDTA and 10% DMSO with 10 nM [9-methyl-3H]BRL-43694 (Perkin Elmer), 3 ug of human 5-HT3 receptor membranes (Perkin Elmer) and 0.5 mg/mL SPA beads (WGA PVT, Amersham Biosciences) in a final volume of 0.2 mL. Binding reactions were set up in wells of PicoPlates-96 (Perkin Elmer) by adding consecutively 50 uL of each competing compound or buffer, SPA beads, the radioligand and 5-HT3 receptor membranes. After an overnight incubation at room temperature on a Nutator mixer, plates were centrifuged for 15 min at 1,500 rpm.",CHEMBL3638654,KI,Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21
CHEMBL103772,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,750.0,nM,CHEMBL4039172,B,Inhibition of serotonin 5-HT3 receptor (unknown origin),CHEMBL4038300,KI,c1ccc(-c2nc(CN3CCN(c4ncccn4)CC3)c[nH]2)cc1
CHEMBL195345,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2.0,nM,CHEMBL4180473,B,Binding affinity to 5-HT3A receptor (unknown origin),CHEMBL4177618,KI,c1ccc(-c2cnc3c(c2)C[C@@]2(CN4CCC2CC4)O3)cc1
CHEMBL4207529,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3100.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,COC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1N=C(c2ccccc2O)S[C@@H]1C
CHEMBL4212435,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,240.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,C[C@@H]1SC(c2ccccc2O)=N[C@H]1Cc1c[nH]cn1
CHEMBL4205064,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,950.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,Oc1ccccc1C1=NC(Cc2c[nH]cn2)CS1
CHEMBL4209942,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,860.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,Oc1ccccc1C1=NC(Cc2c[nH]cn2)C(c2ccccc2)S1
CHEMBL4206418,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6700.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,C[C@@H]1SC(c2ccccc2)=N[C@H]1CO
CHEMBL4215741,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3600.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,CNc1ccccc1C1=N[C@@H](CO)[C@H](C)S1
CHEMBL4210787,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1800.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,C[C@@H]1SC(c2cc3ccccc3cc2O)=N[C@H]1CO
CHEMBL4202582,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2800.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,C[C@@H]1SC(c2c[nH]c3ccccc23)=N[C@H]1CO
CHEMBL4218679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,6700.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,C[C@@H]1SC(c2ccsc2)=N[C@H]1CO
CHEMBL4204576,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,150.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,C[C@@H]1SC(c2ccccc2)=N[C@H]1Cc1c[nH]cn1
CHEMBL4204036,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,77.0,nM,CHEMBL4192995,B,Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis,CHEMBL4190286,KI,C[C@@H]1SC(c2ccccc2)=N[C@@H]1Cc1c[nH]cn1
CHEMBL4218672,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,703.0,nM,CHEMBL4199356,B,Displacement of [3H]LSD from human 5-HT3 receptor expressed in HEK cell membranes after 1.5 hrs by microbeta scintillation counting method,CHEMBL4196105,KI,Fc1ccc(-c2noc3c2CCNCC3)cc1
CHEMBL4218801,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,303.0,nM,CHEMBL4199356,B,Displacement of [3H]LSD from human 5-HT3 receptor expressed in HEK cell membranes after 1.5 hrs by microbeta scintillation counting method,CHEMBL4196105,KI,Clc1ccc(-c2noc3c2CCNCC3)cc1
CHEMBL4215875,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,420.0,nM,CHEMBL4199356,B,Displacement of [3H]LSD from human 5-HT3 receptor expressed in HEK cell membranes after 1.5 hrs by microbeta scintillation counting method,CHEMBL4196105,KI,Cc1ccc(-c2noc3c2CCNCC3)cc1
CHEMBL261010,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.04,nM,CHEMBL4219560,B,Displacement of [3H]granisetron from human 5-HT3A receptor expressed in HEK293 cells by scintillation counting method,CHEMBL4219030,KI,CN1CCN(c2nc3ccccc3nc2Cl)CC1
CHEMBL4458163,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,440.0,nM,CHEMBL4354326,B,Displacement of [3H]BRL 43694 from human 5HT3R by radioligand displacement assay,CHEMBL4351014,KI,Fc1ccc(-c2ccc(-c3cn([C@H]4CN5CCC4CC5)nn3)s2)cn1
CHEMBL4533685,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,560.0,nM,CHEMBL4354326,B,Displacement of [3H]BRL 43694 from human 5HT3R by radioligand displacement assay,CHEMBL4351014,KI,c1cc(-c2ccc(-c3cn([C@H]4CN5CCC4CC5)nn3)s2)ccc1CN1CCCCC1
CHEMBL4277264,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7900.0,nM,CHEMBL4392142,B,Displacement of [3H]GR65630 from recombinant human 5HT3 receptor transiently expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,Cc1cc(Oc2nccc3occc23)ccc1-c1c(C)ncc2nccn12
CHEMBL4572614,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,9100.0,nM,CHEMBL4392142,B,Displacement of [3H]GR65630 from recombinant human 5HT3 receptor transiently expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,Cc1ncc2nccn2c1-c1ccc(Oc2nccc3occc23)cc1C(F)(F)F
CHEMBL4469848,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,9300.0,nM,CHEMBL4392142,B,Displacement of [3H]GR65630 from recombinant human 5HT3 receptor transiently expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,FC(F)(F)c1cc(Oc2nccc3occc23)ccc1-c1cccc2nccn12
CHEMBL4466483,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,7600.0,nM,CHEMBL4392142,B,Displacement of [3H]GR65630 from recombinant human 5HT3 receptor transiently expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,FC(F)(F)c1cc(Oc2nccc3ccsc23)ccc1-c1cccc2nccn12
CHEMBL4468363,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,12.0,nM,CHEMBL4415155,B,Antagonist activity at 5-HT3 receptor (unknown origin),CHEMBL4414553,KI,O=C(NC1CN2CCC1CC2)c1cc(Cl)cn2ccnc12
CHEMBL4533922,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,26.0,nM,CHEMBL4415155,B,Antagonist activity at 5-HT3 receptor (unknown origin),CHEMBL4414553,KI,Cc1cn2c(N)c(Cl)cc(C(=O)NCC3CCNCC3)c2n1
CHEMBL4876193,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,816.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Cc1cccc(-c2n[nH]cc2N2CCCNCC2)c1
CHEMBL4863868,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,744.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Cc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1
CHEMBL4877603,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,300.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Clc1cccc(-c2n[nH]cc2N2CCCNCC2)c1
CHEMBL4854605,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,498.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Clc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1
CHEMBL4866412,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,656.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Fc1cccc(-c2n[nH]cc2N2CCCNCC2)c1
CHEMBL4869695,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1808.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Fc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1
CHEMBL4867560,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2225.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,COc1ccccc1-c1n[nH]cc1N1CCCNCC1
CHEMBL4860503,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1025.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,COc1cccc(-c2n[nH]cc2N2CCCNCC2)c1
CHEMBL4863036,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1230.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,COc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1
CHEMBL4868035,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2097.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,c1ccc(-c2n[nH]cc2N2CCCNCC2)cc1
CHEMBL4870675,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2095.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,COc1cccc(-c2n[nH]cc2N2CCNCC2)c1
CHEMBL4848305,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,806.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Clc1cccc(-c2n[nH]cc2N2CCNCC2)c1
CHEMBL4858338,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1789.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Clc1ccc(-c2n[nH]cc2N2CCNCC2)cc1
CHEMBL4874854,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1955.0,nM,CHEMBL4828361,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4825758,KI,Fc1ccccc1-c1n[nH]cc1N1CCNCC1
CHEMBL4867565,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,0.93,nM,CHEMBL4844533,B,Binding affinity to 5HT3 receptor (unknown origin),CHEMBL4842371,KI,O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21
CHEMBL3480577,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3988.75,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507309,KI,Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1
CHEMBL3480577,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3715.35,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507309,KI,Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1
CHEMBL3342332,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1142.6,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507311,KI,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1
CHEMBL3342332,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1071.52,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507311,KI,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1
CHEMBL4520293,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2956.83,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507322,KI,CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1
CHEMBL4520293,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2884.03,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507322,KI,CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1
CHEMBL4534980,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3626.13,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507322,KI,CN(C)[C@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1
CHEMBL4534980,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3548.13,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507322,KI,CN(C)[C@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1
CHEMBL4798829,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5461.68,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507313,KI,c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1
CHEMBL4798829,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5370.32,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4507313,KI,c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1
CHEMBL4639128,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4456.49,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4630907,KI,COCc1nc2cnc3cc(-c4c(C)noc4C)c(OC[C@H]4CCNC4)cc3c2n1[C@H](C)c1ccccc1
CHEMBL4639128,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,4466.84,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4630907,KI,COCc1nc2cnc3cc(-c4c(C)noc4C)c(OC[C@H]4CCNC4)cc3c2n1[C@H](C)c1ccccc1
CHEMBL3931889,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1000.0,nM,CHEMBL5039782,B,Binding affinity to 5-HT3R (unknown origin),CHEMBL5038590,KI,COc1ccccc1-c1cc(CN(C)C)ccc1Cl
CHEMBL5077293,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,590.0,nM,CHEMBL5039782,B,Binding affinity to 5-HT3R (unknown origin),CHEMBL5038590,KI,COc1ccccc1-c1cc(C2CCNC2)ccc1Cl
CHEMBL5083607,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,420.0,nM,CHEMBL5039782,B,Binding affinity to 5-HT3R (unknown origin),CHEMBL5038590,KI,COc1ccccc1-c1cc(C2CCN(C)C2)ccc1Cl
CHEMBL5170784,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2790.0,nM,CHEMBL5135846,B,Binding affinity to 5HT3 receptor (unknown origin) assessed as inhibition constant,CHEMBL5131517,KI,COc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)c(O)c1
CHEMBL5207529,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2785.0,nM,CHEMBL5135846,B,Binding affinity to 5HT3 receptor (unknown origin) assessed as inhibition constant,CHEMBL5131517,KI,COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)cc1OC.Cl
CHEMBL4534980,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3626.0,nM,CHEMBL5214387,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000345a HTR3A,CHEMBL5212743,KI,CN(C)[C@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1
CHEMBL3342332,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1142.6,nM,CHEMBL5213800,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000262b HTR3A,CHEMBL5212743,KI,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1
CHEMBL2104993,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,3.7,nM,CHEMBL5215979,B,Binding affinity to human 5-HT3R assessed as inhibition constant,CHEMBL5214911,KI,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
CHEMBL4642079,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,584.83,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4630901,KI,Cc1c(N2CCNCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl
CHEMBL4642079,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,537.03,nM,CHEMBL4880030,B,GPCRScan assay: inhibition of 5-HT3,CHEMBL4630901,KI,Cc1c(N2CCNCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl
CHEMBL1516474,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,5843.86,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12.O=C(O)/C=C\C(=O)O
CHEMBL1256998,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1307.37,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCCCN1CCC(COC(=O)c2cc(Cl)c(N)c3c2OCCO3)CC1.Cl
CHEMBL59898,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1662.65,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCOC(=O)c1c(C)[nH]c2ccc3c(c12)CN1CCc2cc(OC)ccc2C1O3
CHEMBL542139,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,988.1,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl
CHEMBL543113,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,2066.81,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2.Cl
CHEMBL4743049,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,63.69,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cl.Clc1cccc(COc2cncc(N3CCNCC3)n2)c1
CHEMBL519240,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,351.84,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Nc1nc2c(c(N3CCNCC3)n1)CCC1=C2[C@@H]2CCCC[C@@H]2O1
CHEMBL1633,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,338.93,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O
CHEMBL2164327,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,260.79,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1nn(C)c(C)c1-c1cccc2c1CC[C@H](N(C)C)C2
CHEMBL2105760,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,1528.1,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1
CHEMBL3675743,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,360.29,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(-c2nnc(C3CCNCC3)o2)cc1
CHEMBL5075931,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Ki,=,661.83,nM,CHEMBL5442216,B,"PDSP Secondary Binding target: HTR3A - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12.O=C(O)C(=O)O
CHEMBL68281,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,240.0,nM,CHEMBL619056,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,CHEMBL1134807,EC50,C=CCn1c(N2CCNCC2)nc2ccccc21
CHEMBL11608,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,26000.0,nM,CHEMBL923632,B,Activity at SER3 receptor expressed in HEK293 cells assessed as increase in calcium by calcium imaging assay,CHEMBL1147087,EC50,NCCc1ccc(O)cc1
CHEMBL53929,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,24.0,nM,CHEMBL923632,B,Activity at SER3 receptor expressed in HEK293 cells assessed as increase in calcium by calcium imaging assay,CHEMBL1147087,EC50,NCC(O)c1ccc(O)cc1
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,190.0,nM,CHEMBL3097185,B,Agonist activity at human 5-HT3A receptor D165K mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,190.0,nM,CHEMBL3097186,B,Agonist activity at human 5-HT3A receptor D165A mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,94.0,nM,CHEMBL3097187,B,Agonist activity at human 5-HT3A receptor S163T mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,160.0,nM,CHEMBL3094562,B,Agonist activity at human 5-HT3A receptor S163A mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,130.0,nM,CHEMBL3094564,B,Agonist activity at human 5-HT3A receptor F130A mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,74.0,nM,CHEMBL3094566,B,Agonist activity at human 5-HT3A receptor Y73S mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,450.0,nM,CHEMBL3094567,B,Agonist activity at human 5-HT3A receptor Y73F mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,88.0,nM,CHEMBL3094569,B,Agonist activity at human 5-HT3A receptor Y73A mutant by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,320.0,nM,CHEMBL3094568,B,Agonist activity at human wild type 5-HT3A receptor expressed in HEK293 cells by FLIPR assay,CHEMBL3091286,EC50,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL3261479,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,178.0,nM,CHEMBL3268500,B,Agonist activity at human 5-HT3A receptor expressed in HEK293 cells in presence of carbachol,CHEMBL3259590,EC50,O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261481,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,178.0,nM,CHEMBL3268500,B,Agonist activity at human 5-HT3A receptor expressed in HEK293 cells in presence of carbachol,CHEMBL3259590,EC50,O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261482,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,178.0,nM,CHEMBL3268500,B,Agonist activity at human 5-HT3A receptor expressed in HEK293 cells in presence of carbachol,CHEMBL3259590,EC50,O=C1c2cc(F)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261483,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,178.0,nM,CHEMBL3268500,B,Agonist activity at human 5-HT3A receptor expressed in HEK293 cells in presence of carbachol,CHEMBL3259590,EC50,O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL3261485,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,178.0,nM,CHEMBL3268500,B,Agonist activity at human 5-HT3A receptor expressed in HEK293 cells in presence of carbachol,CHEMBL3259590,EC50,COc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1
CHEMBL3261486,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,178.0,nM,CHEMBL3268500,B,Agonist activity at human 5-HT3A receptor expressed in HEK293 cells in presence of carbachol,CHEMBL3259590,EC50,O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2
CHEMBL4060134,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,25118.86,nM,CHEMBL4012914,B,Inhibition of human serotonin receptor 3,CHEMBL4011625,EC50,Cn1cnc(C(=O)N2CCN(C(=O)c3ccc(Nc4nc5ccccc5n5nnnc45)cc3)CC2)c1
CHEMBL13790,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,EC50,=,3800.0,nM,CHEMBL4219562,B,Agonist activity at human 5-HT43A receptor expressed in Xenopus laevis oocytes,CHEMBL4219030,EC50,N=C(N)NC(=N)Nc1cccc(Cl)c1
CHEMBL499536,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,13000.0,nM,CHEMBL2157809,B,Binding affinity to 5HT3 receptor,CHEMBL2151039,KD,C[C@H](OC(=O)N[C@@H]1CN2CCC1CC2)c1ccccc1F
CHEMBL2322133,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,83.0,nM,CHEMBL2327178,B,Binding affinity to C-terminal-His6-tagged 5HT3A receptor (unknown origin) expressed in HEK293 cells after 2 hrs by fluorimetric analysis,CHEMBL2321670,KD,CN(C)c1ccc2c(-c3ccc(C(=O)NCCCCCNC(=O)CCn4cc(CCN)c5cc(O)ccc54)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.44,nM,CHEMBL3094578,B,Binding affinity to human 5-HT3A receptor D165K mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.37,nM,CHEMBL3094579,B,Binding affinity to human 5-HT3A receptor D165A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.19,nM,CHEMBL3094580,B,Binding affinity to human 5-HT3A receptor S163T mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.36,nM,CHEMBL3094581,B,Binding affinity to human 5-HT3A receptor S163A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.49,nM,CHEMBL3094582,B,Binding affinity to human 5-HT3A receptor F130Y mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.78,nM,CHEMBL3094583,B,Binding affinity to human 5-HT3A receptor F130A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.41,nM,CHEMBL3094585,B,Binding affinity to human 5-HT3A receptor Y73S mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.9,nM,CHEMBL3094586,B,Binding affinity to human 5-HT3A receptor Y73F mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.6,nM,CHEMBL3094587,B,Binding affinity to human 5-HT3A receptor Y73A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL289469,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.53,nM,CHEMBL3094589,B,Binding affinity to human wild type 5-HT3A receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.36,nM,CHEMBL3094578,B,Binding affinity to human 5-HT3A receptor D165K mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.3,nM,CHEMBL3094579,B,Binding affinity to human 5-HT3A receptor D165A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.22,nM,CHEMBL3094580,B,Binding affinity to human 5-HT3A receptor S163T mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.3,nM,CHEMBL3094581,B,Binding affinity to human 5-HT3A receptor S163A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.26,nM,CHEMBL3094582,B,Binding affinity to human 5-HT3A receptor F130Y mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.67,nM,CHEMBL3094583,B,Binding affinity to human 5-HT3A receptor F130A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.61,nM,CHEMBL3094585,B,Binding affinity to human 5-HT3A receptor Y73S mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.25,nM,CHEMBL3094586,B,Binding affinity to human 5-HT3A receptor Y73F mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.87,nM,CHEMBL3094587,B,Binding affinity to human 5-HT3A receptor Y73A mutant after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
CHEMBL1189679,CHEMBL1899,Serotonin 3a (5-HT3a) receptor,Kd,=,0.32,nM,CHEMBL3094589,B,Binding affinity to human wild type 5-HT3A receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis,CHEMBL3091286,KD,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
